[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$ffGa67-s84tcaFRxOOchMROMYZVIeyl31ze6hijIsgoM":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":53,"rows":60},"Sun Pharmaceutical Industries, Inc.",[4],79,false,4,15,40476,3,0,[14,17,20,23,26,28,30,32],{"name":15,"count":16},"Acne Vulgaris",22,{"name":18,"count":19},"Plaque Psoriasis",8,{"name":21,"count":22},"Tinea Pedis",7,{"name":24,"count":25},"Psoriasis",5,{"name":27,"count":25},"Actinic Keratosis",{"name":29,"count":8},"Scalp Psoriasis",{"name":31,"count":8},"Pediculosis",{"name":33,"count":8},"Atopic Dermatitis",[35,40,43,48],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT07144345","Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp","2027-01","Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%",{"nctId":41,"briefTitle":42,"date":38,"intervention":39},"NCT07144852","Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT03898479","Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata","2027-05","CTP-543",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT07133308","Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata","2028-05","Deuruxolitinib",[54,55,56,57,58,59],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[61,90,124,144,169,231,272,317,354,376,407,425,443,461,486,530,563,601,627,645,663,681,699,724,748,770,795,813,875,910,935,953,979,997,1022,1040,1066,1084,1109,1127,1152,1170,1197,1215,1233,1260,1278,1296,1314,1332,1358,1376,1394,1421,1439,1457,1481,1505,1523,1541,1566,1584,1609,1627,1651,1669,1687,1712,1730,1748,1772,1790,1815,1833,1858,1882,1900,1927,1945,1970,1988,2006,2024,2049,2067,2092,2116,2134,2152,2177,2195,2213,2231,2249,2274,2292,2321,2339,2357,2375,2399,2417,2435,2460,2478,2504,2522,2540,2564,2582,2608,2626,2655,2673,2691,2709,2727,2745,2763,2788,2806,2830,2848,2873,2891,2914,2932,2950],{"intervention":39,"totalTrials":62,"cells":63},2,{"EARLY_PHASE1":64,"PHASE1":66,"PHASE2":68,"PHASE3":70,"PHASE4":86,"NA":88},{"trials":65,"activeCount":12},[],{"trials":67,"activeCount":12},[],{"trials":69,"activeCount":12},[],{"trials":71,"activeCount":62,"soonestReadout":38},[72,80],{"nctId":36,"briefTitle":37,"status":73,"phases":74,"primaryCompletion":38,"completion":75,"start":76,"enrollment":77,"conditions":78,"interventions":79},"RECRUITING",[57],"2027-04","2025-11-19",160,[27],[39],{"nctId":41,"briefTitle":42,"status":73,"phases":81,"primaryCompletion":38,"completion":75,"start":82,"enrollment":83,"conditions":84,"interventions":85},[57],"2025-11-29",260,[27],[39],{"trials":87,"activeCount":12},[],{"trials":89,"activeCount":12},[],{"intervention":47,"totalTrials":62,"cells":91},{"EARLY_PHASE1":92,"PHASE1":94,"PHASE2":96,"PHASE3":98,"PHASE4":120,"NA":122},{"trials":93,"activeCount":12},[],{"trials":95,"activeCount":12},[],{"trials":97,"activeCount":12},[],{"trials":99,"activeCount":119,"soonestReadout":46},[100,109],{"nctId":44,"briefTitle":45,"status":101,"phases":102,"primaryCompletion":46,"completion":103,"start":104,"enrollment":105,"conditions":106,"interventions":108},"ACTIVE_NOT_RECRUITING",[56,57],"2027-06","2019-04-04",1000,[107],"Alopecia Areata",[47],{"nctId":110,"briefTitle":111,"status":112,"phases":113,"primaryCompletion":114,"completion":114,"start":115,"enrollment":116,"conditions":117,"interventions":118},"NCT05041803","European Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata","COMPLETED",[57],"2024-07-18","2021-10-19",407,[107],[47],1,{"trials":121,"activeCount":12},[],{"trials":123,"activeCount":12},[],{"intervention":52,"totalTrials":119,"cells":125},{"EARLY_PHASE1":126,"PHASE1":128,"PHASE2":130,"PHASE3":132,"PHASE4":140,"NA":142},{"trials":127,"activeCount":12},[],{"trials":129,"activeCount":12},[],{"trials":131,"activeCount":12},[],{"trials":133,"activeCount":119,"soonestReadout":51},[134],{"nctId":49,"briefTitle":50,"status":73,"phases":135,"primaryCompletion":51,"completion":51,"start":136,"enrollment":137,"conditions":138,"interventions":139},[57],"2025-08-05",355,[107],[52],{"trials":141,"activeCount":12},[],{"trials":143,"activeCount":12},[],{"intervention":145,"totalTrials":119,"cells":146},"Topicort® (desoximetasone) Topical Spray, 0.25%",{"EARLY_PHASE1":147,"PHASE1":149,"PHASE2":151,"PHASE3":153,"PHASE4":155,"NA":167},{"trials":148,"activeCount":12},[],{"trials":150,"activeCount":12},[],{"trials":152,"activeCount":12},[],{"trials":154,"activeCount":12},[],{"trials":156,"activeCount":12},[157],{"nctId":158,"briefTitle":159,"status":112,"phases":160,"primaryCompletion":161,"completion":162,"start":163,"enrollment":164,"conditions":165,"interventions":166},"NCT02340169","Adrenal Suppression and Pharmacokinetics of Topicort® Spray, 0.25% in Pediatric Patients With Plaque Psoriasis",[58],"2019-11-22","2021-11-22","2015-01-23",129,[18],[145],{"trials":168,"activeCount":12},[],{"intervention":170,"totalTrials":25,"cells":171},"DSXS",{"EARLY_PHASE1":172,"PHASE1":174,"PHASE2":176,"PHASE3":198,"PHASE4":227,"NA":229},{"trials":173,"activeCount":12},[],{"trials":175,"activeCount":12},[],{"trials":177,"activeCount":12},[178,188],{"nctId":179,"briefTitle":180,"status":112,"phases":181,"primaryCompletion":182,"completion":183,"start":184,"enrollment":185,"conditions":186,"interventions":187},"NCT02601469","Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque Psoriasis",[56],"2016-12-29","2017-08-25","2015-09-04",26,[18],[170],{"nctId":189,"briefTitle":190,"status":112,"phases":191,"primaryCompletion":192,"completion":183,"start":193,"enrollment":194,"conditions":195,"interventions":197},"NCT02595008","Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Atopic Dermatitis",[56],"2017-02-22","2015-08-28",24,[196],"Dermatitis, Atopic",[170],{"trials":199,"activeCount":12},[200,209,219],{"nctId":201,"briefTitle":202,"status":112,"phases":203,"primaryCompletion":204,"completion":205,"start":184,"enrollment":206,"conditions":207,"interventions":208},"NCT02595073","Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis",[57],"2017-01-17","2017-08-29",124,[33],[170],{"nctId":210,"briefTitle":211,"status":112,"phases":212,"primaryCompletion":213,"completion":214,"start":215,"enrollment":216,"conditions":217,"interventions":218},"NCT02932462","Study to Evaluate Efficacy and Safety of the Topical Product in Patients With Mild to Severe Scalp Psoriasis",[57],"2016-12-01","2017-09-29","2016-03",373,[29],[170],{"nctId":220,"briefTitle":221,"status":112,"phases":222,"primaryCompletion":223,"completion":183,"start":193,"enrollment":224,"conditions":225,"interventions":226},"NCT02618759","Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque Psoriasis",[57],"2017-03-16",119,[18],[170],{"trials":228,"activeCount":12},[],{"trials":230,"activeCount":12},[],{"intervention":232,"totalTrials":11,"cells":233},"Malathion gel 0.5%",{"EARLY_PHASE1":234,"PHASE1":236,"PHASE2":247,"PHASE3":249,"PHASE4":268,"NA":270},{"trials":235,"activeCount":12},[],{"trials":237,"activeCount":12},[238],{"nctId":239,"briefTitle":240,"status":112,"phases":241,"primaryCompletion":242,"completion":242,"start":243,"enrollment":194,"conditions":244,"interventions":245},"NCT00927407","Pharmacokinetics of Malathion Gel 0.5% and Malathion 0.5% Lotion (Ovide) in Patients With Head Lice",[55],"2009-08","2009-07",[31],[232,246],"Malathion lotion 0.5%",{"trials":248,"activeCount":12},[],{"trials":250,"activeCount":12},[251,260],{"nctId":252,"briefTitle":253,"status":112,"phases":254,"primaryCompletion":255,"completion":255,"start":242,"enrollment":256,"conditions":257,"interventions":258},"NCT00963508","Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice",[57],"2010-03",403,[31],[232,259],"Permethrin 1% rinse",{"nctId":261,"briefTitle":253,"status":112,"phases":262,"primaryCompletion":263,"completion":264,"start":242,"enrollment":265,"conditions":266,"interventions":267},"NCT00927472",[57],"2010-05","2010-06",254,[31],[232,259],{"trials":269,"activeCount":12},[],{"trials":271,"activeCount":12},[],{"intervention":273,"totalTrials":11,"cells":274},"DSXS topical",{"EARLY_PHASE1":275,"PHASE1":277,"PHASE2":279,"PHASE3":301,"PHASE4":313,"NA":315},{"trials":276,"activeCount":12},[],{"trials":278,"activeCount":12},[],{"trials":280,"activeCount":12},[281,291],{"nctId":282,"briefTitle":283,"status":112,"phases":284,"primaryCompletion":285,"completion":286,"start":287,"enrollment":288,"conditions":289,"interventions":290},"NCT02932891","An Open Label, Safety Study to Assess the Potential for Adrenal Suppression.",[56],"2017-04-14","2017-12-12","2016-08",28,[33],[273],{"nctId":292,"briefTitle":293,"status":112,"phases":294,"primaryCompletion":295,"completion":296,"start":297,"enrollment":298,"conditions":299,"interventions":300},"NCT02932878","An Open Label, Safety Study to Assess the Potential for Adrenal Suppression",[56],"2017-04-10","2017-10-16","2016-09-02",16,[18],[273],{"trials":302,"activeCount":12},[303],{"nctId":304,"briefTitle":305,"status":112,"phases":306,"primaryCompletion":307,"completion":214,"start":308,"enrollment":309,"conditions":310,"interventions":311},"NCT02933866","Phase III Clinical Study in Patients With Mild to Severe Scalp Psoriasis",[57],"2016-11-16","2016-03-11",371,[29],[273,312],"Vehicle topical",{"trials":314,"activeCount":12},[],{"trials":316,"activeCount":12},[],{"intervention":318,"totalTrials":62,"cells":319},"MALG",{"EARLY_PHASE1":320,"PHASE1":322,"PHASE2":324,"PHASE3":338,"PHASE4":350,"NA":352},{"trials":321,"activeCount":12},[],{"trials":323,"activeCount":12},[],{"trials":325,"activeCount":12},[326],{"nctId":327,"briefTitle":328,"status":329,"phases":330,"primaryCompletion":331,"completion":332,"start":333,"enrollment":334,"conditions":335,"interventions":337},"NCT00291057","Safety and Tolerability of a Novel Malathion Formulation in Infants and Toddlers With Head Lice","TERMINATED",[56],"2006-10","2006-12","2006-02",30,[336],"Lice Infestations",[318],{"trials":339,"activeCount":12},[340],{"nctId":341,"briefTitle":342,"status":112,"phases":343,"primaryCompletion":331,"completion":332,"start":344,"enrollment":345,"conditions":346,"interventions":347},"NCT00244439","Safety and Efficacy of a Novel Malathion Formulation in the Treatment of Head Lice",[57],"2005-12",360,[336],[318,348,349],"Ovide (malathion) lotion 0.05%","Permethrin 1%",{"trials":351,"activeCount":12},[],{"trials":353,"activeCount":12},[],{"intervention":259,"totalTrials":62,"cells":355},{"EARLY_PHASE1":356,"PHASE1":358,"PHASE2":360,"PHASE3":362,"PHASE4":372,"NA":374},{"trials":357,"activeCount":12},[],{"trials":359,"activeCount":12},[],{"trials":361,"activeCount":12},[],{"trials":363,"activeCount":12},[364,368],{"nctId":252,"briefTitle":253,"status":112,"phases":365,"primaryCompletion":255,"completion":255,"start":242,"enrollment":256,"conditions":366,"interventions":367},[57],[31],[232,259],{"nctId":261,"briefTitle":253,"status":112,"phases":369,"primaryCompletion":263,"completion":264,"start":242,"enrollment":265,"conditions":370,"interventions":371},[57],[31],[232,259],{"trials":373,"activeCount":12},[],{"trials":375,"activeCount":12},[],{"intervention":377,"totalTrials":62,"cells":378},"Desoximetasone Spray 0.25%",{"EARLY_PHASE1":379,"PHASE1":381,"PHASE2":383,"PHASE3":385,"PHASE4":403,"NA":405},{"trials":380,"activeCount":12},[],{"trials":382,"activeCount":12},[],{"trials":384,"activeCount":12},[],{"trials":386,"activeCount":12},[387,397],{"nctId":388,"briefTitle":389,"status":112,"phases":390,"primaryCompletion":391,"completion":392,"start":393,"enrollment":394,"conditions":395,"interventions":396},"NCT01206387","Effects of Desoximetasone Spray 0.25% on Moderate to Severe Plaque Psoriasis",[57],"2010-12","2011-01","2010-08",120,[24],[377],{"nctId":398,"briefTitle":399,"status":112,"phases":400,"primaryCompletion":391,"completion":392,"start":393,"enrollment":394,"conditions":401,"interventions":402},"NCT01206660","Effects of Desoximetasone Spray 0.25% in Patients With Moderate to Severe Plaque Psoriasis",[57],[24],[377],{"trials":404,"activeCount":12},[],{"trials":406,"activeCount":12},[],{"intervention":348,"totalTrials":119,"cells":408},{"EARLY_PHASE1":409,"PHASE1":411,"PHASE2":413,"PHASE3":415,"PHASE4":421,"NA":423},{"trials":410,"activeCount":12},[],{"trials":412,"activeCount":12},[],{"trials":414,"activeCount":12},[],{"trials":416,"activeCount":12},[417],{"nctId":341,"briefTitle":342,"status":112,"phases":418,"primaryCompletion":331,"completion":332,"start":344,"enrollment":345,"conditions":419,"interventions":420},[57],[336],[318,348,349],{"trials":422,"activeCount":12},[],{"trials":424,"activeCount":12},[],{"intervention":349,"totalTrials":119,"cells":426},{"EARLY_PHASE1":427,"PHASE1":429,"PHASE2":431,"PHASE3":433,"PHASE4":439,"NA":441},{"trials":428,"activeCount":12},[],{"trials":430,"activeCount":12},[],{"trials":432,"activeCount":12},[],{"trials":434,"activeCount":12},[435],{"nctId":341,"briefTitle":342,"status":112,"phases":436,"primaryCompletion":331,"completion":332,"start":344,"enrollment":345,"conditions":437,"interventions":438},[57],[336],[318,348,349],{"trials":440,"activeCount":12},[],{"trials":442,"activeCount":12},[],{"intervention":312,"totalTrials":119,"cells":444},{"EARLY_PHASE1":445,"PHASE1":447,"PHASE2":449,"PHASE3":451,"PHASE4":457,"NA":459},{"trials":446,"activeCount":12},[],{"trials":448,"activeCount":12},[],{"trials":450,"activeCount":12},[],{"trials":452,"activeCount":12},[453],{"nctId":304,"briefTitle":305,"status":112,"phases":454,"primaryCompletion":307,"completion":214,"start":308,"enrollment":309,"conditions":455,"interventions":456},[57],[29],[273,312],{"trials":458,"activeCount":12},[],{"trials":460,"activeCount":12},[],{"intervention":462,"totalTrials":119,"cells":463},"MALG (malathion) Treatment",{"EARLY_PHASE1":464,"PHASE1":466,"PHASE2":468,"PHASE3":470,"PHASE4":482,"NA":484},{"trials":465,"activeCount":12},[],{"trials":467,"activeCount":12},[],{"trials":469,"activeCount":12},[],{"trials":471,"activeCount":12},[472],{"nctId":473,"briefTitle":474,"status":112,"phases":475,"primaryCompletion":476,"completion":477,"start":478,"enrollment":479,"conditions":480,"interventions":481},"NCT00752973","Safety and Tolerability of a Novel Malathion Formulation in Children Age 6-24 Months With Head Lice",[56,57],"2011-12","2012-01","2008-09",12,[31],[462],{"trials":483,"activeCount":12},[],{"trials":485,"activeCount":12},[],{"intervention":487,"totalTrials":11,"cells":488},"T2000",{"EARLY_PHASE1":489,"PHASE1":491,"PHASE2":493,"PHASE3":524,"PHASE4":526,"NA":528},{"trials":490,"activeCount":12},[],{"trials":492,"activeCount":12},[],{"trials":494,"activeCount":12},[495,505,515],{"nctId":496,"briefTitle":497,"status":329,"phases":498,"primaryCompletion":499,"completion":500,"start":501,"enrollment":25,"conditions":502,"interventions":504},"NCT00655278","T2000 in Essential Tremor - Open Label Continuation",[56],"2009-11","2009-12","2007-08",[503],"Essential Tremor",[487],{"nctId":506,"briefTitle":507,"status":329,"phases":508,"primaryCompletion":509,"completion":510,"start":511,"enrollment":512,"conditions":513,"interventions":514},"NCT00321087","A Study of T2000 in Essential Tremor",[56],"2007-07","2007-12","2006-08",10,[503],[487,487,487],{"nctId":516,"briefTitle":517,"status":329,"phases":518,"primaryCompletion":519,"completion":520,"start":501,"enrollment":25,"conditions":521,"interventions":523},"NCT00506012","Pilot Efficacy Study of T2000 in Myoclonus Dystonia",[56],"2011-08","2011-10",[522],"Myoclonus",[487],{"trials":525,"activeCount":12},[],{"trials":527,"activeCount":12},[],{"trials":529,"activeCount":12},[],{"intervention":531,"totalTrials":62,"cells":532},"DSXS Topical product",{"EARLY_PHASE1":533,"PHASE1":535,"PHASE2":537,"PHASE3":557,"PHASE4":559,"NA":561},{"trials":534,"activeCount":12},[],{"trials":536,"activeCount":12},[],{"trials":538,"activeCount":12},[539,548],{"nctId":540,"briefTitle":541,"status":112,"phases":542,"primaryCompletion":543,"completion":544,"start":545,"enrollment":194,"conditions":546,"interventions":547},"NCT02933528","Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS",[56],"2017-08-11","2017-11-27","2016-07-11",[24],[531],{"nctId":549,"briefTitle":550,"status":112,"phases":551,"primaryCompletion":552,"completion":553,"start":545,"enrollment":11,"conditions":554,"interventions":555},"NCT02933502","Safety Study in Patients With Scalp Psoriasis Suppression Following Maximal Use Treatment With Topical Product",[56],"2017-09-20","2018-01-02",[29],[556],"DSXS topical product",{"trials":558,"activeCount":12},[],{"trials":560,"activeCount":12},[],{"trials":562,"activeCount":12},[],{"intervention":564,"totalTrials":62,"cells":565},"Vehicle of test product",{"EARLY_PHASE1":566,"PHASE1":568,"PHASE2":582,"PHASE3":595,"PHASE4":597,"NA":599},{"trials":567,"activeCount":12},[],{"trials":569,"activeCount":12},[570],{"nctId":571,"briefTitle":572,"status":112,"phases":573,"primaryCompletion":574,"completion":575,"start":576,"enrollment":577,"conditions":578,"interventions":579},"NCT01769235","Study Comparing Clindamycin Phosphate and Benzoyl Peroxide Gel to Acanya® Gel and Both to a Vehicle Control in the Treatment of Acne Vulgaris",[55],"2013-09","2013-12","2012-11",1215,[15],[580,581,564],"Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%\u002F2.5%","Acanya® Gel, 1.2%\u002F2.5%",{"trials":583,"activeCount":12},[584],{"nctId":585,"briefTitle":586,"status":112,"phases":587,"primaryCompletion":588,"completion":588,"start":589,"enrollment":590,"conditions":591,"interventions":593},"NCT02343627","Safety and Efficacy of NVXT Solution in Mild-to-Moderate Fungal Infection of the Toe Nail",[56],"2016-01","2014-12",47,[592],"Onychomycosis",[594,564],"NVXT Solution",{"trials":596,"activeCount":12},[],{"trials":598,"activeCount":12},[],{"trials":600,"activeCount":12},[],{"intervention":602,"totalTrials":119,"cells":603},"Desoximetasone 0.05% once daily",{"EARLY_PHASE1":604,"PHASE1":606,"PHASE2":608,"PHASE3":621,"PHASE4":623,"NA":625},{"trials":605,"activeCount":12},[],{"trials":607,"activeCount":12},[],{"trials":609,"activeCount":12},[610],{"nctId":611,"briefTitle":612,"status":112,"phases":613,"primaryCompletion":263,"completion":263,"start":499,"enrollment":614,"conditions":615,"interventions":616},"NCT01018134","Desoximetasone Spray 0.05%, 0.25%; Dose Ranging Study",[56],151,[24],[602,617,618,618,619,620],"Desoximetasone 0.05% twice daily","Desoximetasone 0.25% once daily","Vehicle once daily","Vehicle twice daily",{"trials":622,"activeCount":12},[],{"trials":624,"activeCount":12},[],{"trials":626,"activeCount":12},[],{"intervention":617,"totalTrials":119,"cells":628},{"EARLY_PHASE1":629,"PHASE1":631,"PHASE2":633,"PHASE3":639,"PHASE4":641,"NA":643},{"trials":630,"activeCount":12},[],{"trials":632,"activeCount":12},[],{"trials":634,"activeCount":12},[635],{"nctId":611,"briefTitle":612,"status":112,"phases":636,"primaryCompletion":263,"completion":263,"start":499,"enrollment":614,"conditions":637,"interventions":638},[56],[24],[602,617,618,618,619,620],{"trials":640,"activeCount":12},[],{"trials":642,"activeCount":12},[],{"trials":644,"activeCount":12},[],{"intervention":618,"totalTrials":119,"cells":646},{"EARLY_PHASE1":647,"PHASE1":649,"PHASE2":651,"PHASE3":657,"PHASE4":659,"NA":661},{"trials":648,"activeCount":12},[],{"trials":650,"activeCount":12},[],{"trials":652,"activeCount":12},[653],{"nctId":611,"briefTitle":612,"status":112,"phases":654,"primaryCompletion":263,"completion":263,"start":499,"enrollment":614,"conditions":655,"interventions":656},[56],[24],[602,617,618,618,619,620],{"trials":658,"activeCount":12},[],{"trials":660,"activeCount":12},[],{"trials":662,"activeCount":12},[],{"intervention":619,"totalTrials":119,"cells":664},{"EARLY_PHASE1":665,"PHASE1":667,"PHASE2":669,"PHASE3":675,"PHASE4":677,"NA":679},{"trials":666,"activeCount":12},[],{"trials":668,"activeCount":12},[],{"trials":670,"activeCount":12},[671],{"nctId":611,"briefTitle":612,"status":112,"phases":672,"primaryCompletion":263,"completion":263,"start":499,"enrollment":614,"conditions":673,"interventions":674},[56],[24],[602,617,618,618,619,620],{"trials":676,"activeCount":12},[],{"trials":678,"activeCount":12},[],{"trials":680,"activeCount":12},[],{"intervention":620,"totalTrials":119,"cells":682},{"EARLY_PHASE1":683,"PHASE1":685,"PHASE2":687,"PHASE3":693,"PHASE4":695,"NA":697},{"trials":684,"activeCount":12},[],{"trials":686,"activeCount":12},[],{"trials":688,"activeCount":12},[689],{"nctId":611,"briefTitle":612,"status":112,"phases":690,"primaryCompletion":263,"completion":263,"start":499,"enrollment":614,"conditions":691,"interventions":692},[56],[24],[602,617,618,618,619,620],{"trials":694,"activeCount":12},[],{"trials":696,"activeCount":12},[],{"trials":698,"activeCount":12},[],{"intervention":700,"totalTrials":119,"cells":701},"ADPS topical product",{"EARLY_PHASE1":702,"PHASE1":704,"PHASE2":706,"PHASE3":718,"PHASE4":720,"NA":722},{"trials":703,"activeCount":12},[],{"trials":705,"activeCount":12},[],{"trials":707,"activeCount":12},[708],{"nctId":709,"briefTitle":710,"status":112,"phases":711,"primaryCompletion":712,"completion":713,"start":714,"enrollment":715,"conditions":716,"interventions":717},"NCT02935036","Efficacy Study in Patients With Acne Vulgaris.",[56],"2017-01-24","2017-03-21","2016-10-03",294,[15],[700],{"trials":719,"activeCount":12},[],{"trials":721,"activeCount":12},[],{"trials":723,"activeCount":12},[],{"intervention":725,"totalTrials":119,"cells":726},"DSXS1411",{"EARLY_PHASE1":727,"PHASE1":729,"PHASE2":731,"PHASE3":742,"PHASE4":744,"NA":746},{"trials":728,"activeCount":12},[],{"trials":730,"activeCount":12},[],{"trials":732,"activeCount":12},[733],{"nctId":734,"briefTitle":735,"status":112,"phases":736,"primaryCompletion":737,"completion":738,"start":739,"enrollment":614,"conditions":740,"interventions":741},"NCT02413229","A Randomized Double Blind Vehicle Controlled Dose Ranging Parallel Design Multiple Site Clinical Study",[56],"2015-09-14","2016-01-29","2015-04",[18],[725],{"trials":743,"activeCount":12},[],{"trials":745,"activeCount":12},[],{"trials":747,"activeCount":12},[],{"intervention":749,"totalTrials":119,"cells":750},"Desoximetasone 0.25% spray",{"EARLY_PHASE1":751,"PHASE1":753,"PHASE2":755,"PHASE3":764,"PHASE4":766,"NA":768},{"trials":752,"activeCount":12},[],{"trials":754,"activeCount":12},[],{"trials":756,"activeCount":12},[757],{"nctId":758,"briefTitle":759,"status":112,"phases":760,"primaryCompletion":264,"completion":264,"start":761,"enrollment":194,"conditions":762,"interventions":763},"NCT01043393","Desoximetasone Spray 0.25%, Hypothalamic Pituitary Adrenal (HPA) Axis Study",[56],"2010-02",[24],[749],{"trials":765,"activeCount":12},[],{"trials":767,"activeCount":12},[],{"trials":769,"activeCount":12},[],{"intervention":771,"totalTrials":119,"cells":772},"NVXT topical",{"EARLY_PHASE1":773,"PHASE1":775,"PHASE2":777,"PHASE3":789,"PHASE4":791,"NA":793},{"trials":774,"activeCount":12},[],{"trials":776,"activeCount":12},[],{"trials":778,"activeCount":12},[779],{"nctId":780,"briefTitle":781,"status":112,"phases":782,"primaryCompletion":783,"completion":784,"start":785,"enrollment":786,"conditions":787,"interventions":788},"NCT02933879","Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multi-Site Phase 2b Clinical Study",[56],"2018-03-06","2018-06-21","2016-03-21",184,[592],[771],{"trials":790,"activeCount":12},[],{"trials":792,"activeCount":12},[],{"trials":794,"activeCount":12},[],{"intervention":594,"totalTrials":119,"cells":796},{"EARLY_PHASE1":797,"PHASE1":799,"PHASE2":801,"PHASE3":807,"PHASE4":809,"NA":811},{"trials":798,"activeCount":12},[],{"trials":800,"activeCount":12},[],{"trials":802,"activeCount":12},[803],{"nctId":585,"briefTitle":586,"status":112,"phases":804,"primaryCompletion":588,"completion":588,"start":589,"enrollment":590,"conditions":805,"interventions":806},[56],[592],[594,564],{"trials":808,"activeCount":12},[],{"trials":810,"activeCount":12},[],{"trials":812,"activeCount":12},[],{"intervention":814,"totalTrials":8,"cells":815},"Vehicle of the test product",{"EARLY_PHASE1":816,"PHASE1":839,"PHASE2":867,"PHASE3":869,"PHASE4":871,"NA":873},{"trials":817,"activeCount":12},[818,829],{"nctId":819,"briefTitle":820,"status":112,"phases":821,"primaryCompletion":822,"completion":822,"start":823,"enrollment":824,"conditions":825,"interventions":826},"NCT03433378","To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.05% and RLD in the Treatment of Acne Vulgaris",[54],"2018-01-26","2017-08-04",700,[15],[827,828,814],"Tretinoin cream, 0.05%","RETIN-A® (tretinoin) cream, 0.05%",{"nctId":830,"briefTitle":831,"status":112,"phases":832,"primaryCompletion":822,"completion":822,"start":833,"enrollment":834,"conditions":835,"interventions":836},"NCT03427554","To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.1% and RLD in the Treatment of Acne Vulgaris",[54],"2017-08-21",455,[15],[837,838,814],"Tretinoin cream 0.1%","RETIN-A® Cream",{"trials":840,"activeCount":12},[841,855],{"nctId":842,"briefTitle":843,"status":112,"phases":844,"primaryCompletion":845,"completion":846,"start":847,"enrollment":848,"conditions":849,"interventions":851},"NCT03257943","A Bioequivalence Study, Comparing Two Formulations of Ivermectin Lotion, 0.5%",[55],"2017-06-27","2017-08-18","2017-03-20",413,[850],"Lice; Head Lice",[852,853,854],"Ivermectin Lotion, 0.5%","SKLICE (ivermectin) Lotion, 0.5%","Vehicle of the Test product",{"nctId":856,"briefTitle":857,"status":112,"phases":858,"primaryCompletion":859,"completion":860,"start":286,"enrollment":861,"conditions":862,"interventions":864},"NCT03689010","To Evaluate the Therapeutic Equivalence and Safety in Treatment of Moderate Facial Rosacea",[55],"2018-08-09","2018-09-28",1116,[863],"Rosacea",[865,866,814],"Azelaic acid foam 15%","Finacea® (Azelaic acid Foam) 15%",{"trials":868,"activeCount":12},[],{"trials":870,"activeCount":12},[],{"trials":872,"activeCount":12},[],{"trials":874,"activeCount":12},[],{"intervention":876,"totalTrials":62,"cells":877},"Trifarotene Cream 0.005%",{"EARLY_PHASE1":878,"PHASE1":880,"PHASE2":902,"PHASE3":904,"PHASE4":906,"NA":908},{"trials":879,"activeCount":12},[],{"trials":881,"activeCount":12},[882,892],{"nctId":883,"briefTitle":884,"status":112,"phases":885,"primaryCompletion":886,"completion":886,"start":887,"enrollment":888,"conditions":889,"interventions":890},"NCT06063473","A Study Comparing Trifarotene Cream 0.005% to AKLIEF® Cream in the Treatment of Acne Vulgaris",[55],"2023-07-13","2023-02-22",762,[15],[876,891],"AKLIEF® Cream",{"nctId":893,"briefTitle":894,"status":112,"phases":895,"primaryCompletion":896,"completion":897,"start":896,"enrollment":105,"conditions":898,"interventions":899},"NCT06733402","A Study Comparing Trifarotene Cream 0.005% to AKLIEF® CREAM (US REFERENCE LISTED DRUG), AKLIEF™ CREAM (CANADIAN REFERENCE PRODUCT) in the Treatment of Acne Vulgaris",[55],"2024-06-20","2024-11-09",[15],[876,900,901],"AKLIEF® Cream (Trifarotene 0.005%) US REFERENCE LISTED DRUG","AKLIEF® Cream (Trifarotene 50 mcg\u002Fg) CANADIAN REFERENCE PRODUCT",{"trials":903,"activeCount":12},[],{"trials":905,"activeCount":12},[],{"trials":907,"activeCount":12},[],{"trials":909,"activeCount":12},[],{"intervention":911,"totalTrials":119,"cells":912},"Betamethasone Scalp Suspension 0.064%;0.0005%",{"EARLY_PHASE1":913,"PHASE1":915,"PHASE2":927,"PHASE3":929,"PHASE4":931,"NA":933},{"trials":914,"activeCount":12},[],{"trials":916,"activeCount":12},[917],{"nctId":918,"briefTitle":919,"status":112,"phases":920,"primaryCompletion":921,"completion":921,"start":922,"enrollment":923,"conditions":924,"interventions":925},"NCT03880357","To Evaluate the Therapeutic Equivalence and Safety in Treatment of Scalp Psoriasis",[55],"2019-03-15","2018-10-22",485,[29],[911,926],"Taclonex®",{"trials":928,"activeCount":12},[],{"trials":930,"activeCount":12},[],{"trials":932,"activeCount":12},[],{"trials":934,"activeCount":12},[],{"intervention":926,"totalTrials":119,"cells":936},{"EARLY_PHASE1":937,"PHASE1":939,"PHASE2":945,"PHASE3":947,"PHASE4":949,"NA":951},{"trials":938,"activeCount":12},[],{"trials":940,"activeCount":12},[941],{"nctId":918,"briefTitle":919,"status":112,"phases":942,"primaryCompletion":921,"completion":921,"start":922,"enrollment":923,"conditions":943,"interventions":944},[55],[29],[911,926],{"trials":946,"activeCount":12},[],{"trials":948,"activeCount":12},[],{"trials":950,"activeCount":12},[],{"trials":952,"activeCount":12},[],{"intervention":954,"totalTrials":119,"cells":955},"Naftifine HCl Cream 1%",{"EARLY_PHASE1":956,"PHASE1":958,"PHASE2":971,"PHASE3":973,"PHASE4":975,"NA":977},{"trials":957,"activeCount":12},[],{"trials":959,"activeCount":12},[960],{"nctId":961,"briefTitle":962,"status":112,"phases":963,"primaryCompletion":964,"completion":965,"start":966,"enrollment":967,"conditions":968,"interventions":969},"NCT01580891","Evaluate the Clinical Equivalence of Two Naftifine HCl 1% Creams in Patients With Interdigital Tinea Pedis",[55],"2013-03","2013-07","2012-05",1053,[21],[954,970],"Naftin® (Naftifine HCl) Cream 1%",{"trials":972,"activeCount":12},[],{"trials":974,"activeCount":12},[],{"trials":976,"activeCount":12},[],{"trials":978,"activeCount":12},[],{"intervention":970,"totalTrials":119,"cells":980},{"EARLY_PHASE1":981,"PHASE1":983,"PHASE2":989,"PHASE3":991,"PHASE4":993,"NA":995},{"trials":982,"activeCount":12},[],{"trials":984,"activeCount":12},[985],{"nctId":961,"briefTitle":962,"status":112,"phases":986,"primaryCompletion":964,"completion":965,"start":966,"enrollment":967,"conditions":987,"interventions":988},[55],[21],[954,970],{"trials":990,"activeCount":12},[],{"trials":992,"activeCount":12},[],{"trials":994,"activeCount":12},[],{"trials":996,"activeCount":12},[],{"intervention":998,"totalTrials":119,"cells":999},"Clindamycin and Benzoyl Peroxide Gel 1%5%",{"EARLY_PHASE1":1000,"PHASE1":1002,"PHASE2":1014,"PHASE3":1016,"PHASE4":1018,"NA":1020},{"trials":1001,"activeCount":12},[],{"trials":1003,"activeCount":12},[1004],{"nctId":1005,"briefTitle":1006,"status":112,"phases":1007,"primaryCompletion":1008,"completion":1009,"start":1010,"enrollment":105,"conditions":1011,"interventions":1012},"NCT02595034","A Study CLBG and Benzoyl Peroxide Gel 1%\u002F5% to BenzaClin® Gel in the Treatment of Acne Vulgaris",[55],"2015-10","2015-11","2015-01",[15],[998,1013],"BenzaClin® Topical Gel",{"trials":1015,"activeCount":12},[],{"trials":1017,"activeCount":12},[],{"trials":1019,"activeCount":12},[],{"trials":1021,"activeCount":12},[],{"intervention":1013,"totalTrials":119,"cells":1023},{"EARLY_PHASE1":1024,"PHASE1":1026,"PHASE2":1032,"PHASE3":1034,"PHASE4":1036,"NA":1038},{"trials":1025,"activeCount":12},[],{"trials":1027,"activeCount":12},[1028],{"nctId":1005,"briefTitle":1006,"status":112,"phases":1029,"primaryCompletion":1008,"completion":1009,"start":1010,"enrollment":105,"conditions":1030,"interventions":1031},[55],[15],[998,1013],{"trials":1033,"activeCount":12},[],{"trials":1035,"activeCount":12},[],{"trials":1037,"activeCount":12},[],{"trials":1039,"activeCount":12},[],{"intervention":1041,"totalTrials":119,"cells":1042},"Naftifine Hydrochloride Cream 2%",{"EARLY_PHASE1":1043,"PHASE1":1045,"PHASE2":1058,"PHASE3":1060,"PHASE4":1062,"NA":1064},{"trials":1044,"activeCount":12},[],{"trials":1046,"activeCount":12},[1047],{"nctId":1048,"briefTitle":1049,"status":112,"phases":1050,"primaryCompletion":1051,"completion":1052,"start":1053,"enrollment":1054,"conditions":1055,"interventions":1056},"NCT02132260","Evaluate the Safety and Efficacy of Naftifine Hydrochloride Cream 2% and Naftin® Cream 2% in Patients With Tinea Pedis",[55],"2014-02","2014-03","2013-08",890,[21],[1041,1057],"Naftin® (Naftifine Hydrochloride) Cream 2%",{"trials":1059,"activeCount":12},[],{"trials":1061,"activeCount":12},[],{"trials":1063,"activeCount":12},[],{"trials":1065,"activeCount":12},[],{"intervention":1057,"totalTrials":119,"cells":1067},{"EARLY_PHASE1":1068,"PHASE1":1070,"PHASE2":1076,"PHASE3":1078,"PHASE4":1080,"NA":1082},{"trials":1069,"activeCount":12},[],{"trials":1071,"activeCount":12},[1072],{"nctId":1048,"briefTitle":1049,"status":112,"phases":1073,"primaryCompletion":1051,"completion":1052,"start":1053,"enrollment":1054,"conditions":1074,"interventions":1075},[55],[21],[1041,1057],{"trials":1077,"activeCount":12},[],{"trials":1079,"activeCount":12},[],{"trials":1081,"activeCount":12},[],{"trials":1083,"activeCount":12},[],{"intervention":1085,"totalTrials":119,"cells":1086},"Azelaic Acid 15% topical gel",{"EARLY_PHASE1":1087,"PHASE1":1089,"PHASE2":1101,"PHASE3":1103,"PHASE4":1105,"NA":1107},{"trials":1088,"activeCount":12},[],{"trials":1090,"activeCount":12},[1091],{"nctId":1092,"briefTitle":1093,"status":112,"phases":1094,"primaryCompletion":1095,"completion":1096,"start":1097,"enrollment":105,"conditions":1098,"interventions":1099},"NCT03094403","To Evaluate the Therapeutic Equivalence and Safety of Azelaic Acid 15% Topical Gel",[55],"2017-03-31","2017-04-01","2016-07-01",[863],[1085,1100],"Finacea® (azelaic acid) Gel, 15%",{"trials":1102,"activeCount":12},[],{"trials":1104,"activeCount":12},[],{"trials":1106,"activeCount":12},[],{"trials":1108,"activeCount":12},[],{"intervention":1100,"totalTrials":119,"cells":1110},{"EARLY_PHASE1":1111,"PHASE1":1113,"PHASE2":1119,"PHASE3":1121,"PHASE4":1123,"NA":1125},{"trials":1112,"activeCount":12},[],{"trials":1114,"activeCount":12},[1115],{"nctId":1092,"briefTitle":1093,"status":112,"phases":1116,"primaryCompletion":1095,"completion":1096,"start":1097,"enrollment":105,"conditions":1117,"interventions":1118},[55],[863],[1085,1100],{"trials":1120,"activeCount":12},[],{"trials":1122,"activeCount":12},[],{"trials":1124,"activeCount":12},[],{"trials":1126,"activeCount":12},[],{"intervention":1128,"totalTrials":119,"cells":1129},"Adapalene\u002FBP gel, 0.3%\u002F2.5%",{"EARLY_PHASE1":1130,"PHASE1":1132,"PHASE2":1144,"PHASE3":1146,"PHASE4":1148,"NA":1150},{"trials":1131,"activeCount":12},[],{"trials":1133,"activeCount":12},[1134],{"nctId":1135,"briefTitle":1136,"status":112,"phases":1137,"primaryCompletion":1138,"completion":215,"start":1139,"enrollment":1140,"conditions":1141,"interventions":1142},"NCT02709902","Study Comparing Adapalene\u002FBP Gel to EPIDUO® FORTE and Both to a Placebo Control in Treatment of Acne Vulgaris",[55],"2016-02","2015-09",460,[15],[1128,1143],"EPIDUO® FORTE",{"trials":1145,"activeCount":12},[],{"trials":1147,"activeCount":12},[],{"trials":1149,"activeCount":12},[],{"trials":1151,"activeCount":12},[],{"intervention":1143,"totalTrials":119,"cells":1153},{"EARLY_PHASE1":1154,"PHASE1":1156,"PHASE2":1162,"PHASE3":1164,"PHASE4":1166,"NA":1168},{"trials":1155,"activeCount":12},[],{"trials":1157,"activeCount":12},[1158],{"nctId":1135,"briefTitle":1136,"status":112,"phases":1159,"primaryCompletion":1138,"completion":215,"start":1139,"enrollment":1140,"conditions":1160,"interventions":1161},[55],[15],[1128,1143],{"trials":1163,"activeCount":12},[],{"trials":1165,"activeCount":12},[],{"trials":1167,"activeCount":12},[],{"trials":1169,"activeCount":12},[],{"intervention":1171,"totalTrials":119,"cells":1172},"Mupirocin Calcium Cream, 2%",{"EARLY_PHASE1":1173,"PHASE1":1175,"PHASE2":1189,"PHASE3":1191,"PHASE4":1193,"NA":1195},{"trials":1174,"activeCount":12},[],{"trials":1176,"activeCount":12},[1177],{"nctId":1178,"briefTitle":1179,"status":112,"phases":1180,"primaryCompletion":1051,"completion":1181,"start":1182,"enrollment":1183,"conditions":1184,"interventions":1186},"NCT01876550","A Study to Evaluate the Safety and Bioequivalence of Mupirocin Calcium Cream, 2% and Bactroban® Cream and Compare Both to a Vehicle in Treatment of Secondarily Infected Traumatic Skin Lesions.",[55],"2019-05-06","2013-02",1902,[1185],"Secondarily Infected Traumatic Skin Lesions",[1171,1187,1188],"Bactroban® Cream","Cream vehicle of test product",{"trials":1190,"activeCount":12},[],{"trials":1192,"activeCount":12},[],{"trials":1194,"activeCount":12},[],{"trials":1196,"activeCount":12},[],{"intervention":1187,"totalTrials":119,"cells":1198},{"EARLY_PHASE1":1199,"PHASE1":1201,"PHASE2":1207,"PHASE3":1209,"PHASE4":1211,"NA":1213},{"trials":1200,"activeCount":12},[],{"trials":1202,"activeCount":12},[1203],{"nctId":1178,"briefTitle":1179,"status":112,"phases":1204,"primaryCompletion":1051,"completion":1181,"start":1182,"enrollment":1183,"conditions":1205,"interventions":1206},[55],[1185],[1171,1187,1188],{"trials":1208,"activeCount":12},[],{"trials":1210,"activeCount":12},[],{"trials":1212,"activeCount":12},[],{"trials":1214,"activeCount":12},[],{"intervention":1188,"totalTrials":119,"cells":1216},{"EARLY_PHASE1":1217,"PHASE1":1219,"PHASE2":1225,"PHASE3":1227,"PHASE4":1229,"NA":1231},{"trials":1218,"activeCount":12},[],{"trials":1220,"activeCount":12},[1221],{"nctId":1178,"briefTitle":1179,"status":112,"phases":1222,"primaryCompletion":1051,"completion":1181,"start":1182,"enrollment":1183,"conditions":1223,"interventions":1224},[55],[1185],[1171,1187,1188],{"trials":1226,"activeCount":12},[],{"trials":1228,"activeCount":12},[],{"trials":1230,"activeCount":12},[],{"trials":1232,"activeCount":12},[],{"intervention":1234,"totalTrials":119,"cells":1235},"Butenafine cream 1% manufactured by Taro",{"EARLY_PHASE1":1236,"PHASE1":1238,"PHASE2":1252,"PHASE3":1254,"PHASE4":1256,"NA":1258},{"trials":1237,"activeCount":12},[],{"trials":1239,"activeCount":12},[1240],{"nctId":1241,"briefTitle":1242,"status":112,"phases":1243,"primaryCompletion":1244,"completion":1245,"start":1246,"enrollment":1247,"conditions":1248,"interventions":1249},"NCT00835510","Clinical Equivalence of Two Butenafine Hydrochloride 1% Creams in Patients With Interdigital Tinea Pedis",[55],"2008-10","2008-12","2008-06",548,[21],[1234,1250,1251],"Lotrimin Ultra (butenafine) 1%","Butenafine Vehicle manufactured by Taro",{"trials":1253,"activeCount":12},[],{"trials":1255,"activeCount":12},[],{"trials":1257,"activeCount":12},[],{"trials":1259,"activeCount":12},[],{"intervention":1250,"totalTrials":119,"cells":1261},{"EARLY_PHASE1":1262,"PHASE1":1264,"PHASE2":1270,"PHASE3":1272,"PHASE4":1274,"NA":1276},{"trials":1263,"activeCount":12},[],{"trials":1265,"activeCount":12},[1266],{"nctId":1241,"briefTitle":1242,"status":112,"phases":1267,"primaryCompletion":1244,"completion":1245,"start":1246,"enrollment":1247,"conditions":1268,"interventions":1269},[55],[21],[1234,1250,1251],{"trials":1271,"activeCount":12},[],{"trials":1273,"activeCount":12},[],{"trials":1275,"activeCount":12},[],{"trials":1277,"activeCount":12},[],{"intervention":1251,"totalTrials":119,"cells":1279},{"EARLY_PHASE1":1280,"PHASE1":1282,"PHASE2":1288,"PHASE3":1290,"PHASE4":1292,"NA":1294},{"trials":1281,"activeCount":12},[],{"trials":1283,"activeCount":12},[1284],{"nctId":1241,"briefTitle":1242,"status":112,"phases":1285,"primaryCompletion":1244,"completion":1245,"start":1246,"enrollment":1247,"conditions":1286,"interventions":1287},[55],[21],[1234,1250,1251],{"trials":1289,"activeCount":12},[],{"trials":1291,"activeCount":12},[],{"trials":1293,"activeCount":12},[],{"trials":1295,"activeCount":12},[],{"intervention":852,"totalTrials":119,"cells":1297},{"EARLY_PHASE1":1298,"PHASE1":1300,"PHASE2":1306,"PHASE3":1308,"PHASE4":1310,"NA":1312},{"trials":1299,"activeCount":12},[],{"trials":1301,"activeCount":12},[1302],{"nctId":842,"briefTitle":843,"status":112,"phases":1303,"primaryCompletion":845,"completion":846,"start":847,"enrollment":848,"conditions":1304,"interventions":1305},[55],[850],[852,853,854],{"trials":1307,"activeCount":12},[],{"trials":1309,"activeCount":12},[],{"trials":1311,"activeCount":12},[],{"trials":1313,"activeCount":12},[],{"intervention":853,"totalTrials":119,"cells":1315},{"EARLY_PHASE1":1316,"PHASE1":1318,"PHASE2":1324,"PHASE3":1326,"PHASE4":1328,"NA":1330},{"trials":1317,"activeCount":12},[],{"trials":1319,"activeCount":12},[1320],{"nctId":842,"briefTitle":843,"status":112,"phases":1321,"primaryCompletion":845,"completion":846,"start":847,"enrollment":848,"conditions":1322,"interventions":1323},[55],[850],[852,853,854],{"trials":1325,"activeCount":12},[],{"trials":1327,"activeCount":12},[],{"trials":1329,"activeCount":12},[],{"trials":1331,"activeCount":12},[],{"intervention":1333,"totalTrials":119,"cells":1334},"Imiquimod Topical Cream 3.75%",{"EARLY_PHASE1":1335,"PHASE1":1337,"PHASE2":1350,"PHASE3":1352,"PHASE4":1354,"NA":1356},{"trials":1336,"activeCount":12},[],{"trials":1338,"activeCount":12},[1339],{"nctId":1340,"briefTitle":1341,"status":112,"phases":1342,"primaryCompletion":1343,"completion":575,"start":1344,"enrollment":1345,"conditions":1346,"interventions":1347},"NCT01788007","Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.",[55],"2013-10","2013-01",443,[27],[1333,1348,1349],"Zyclara® (imiquimod) Topical Cream 3.75%","Vehicle Topical Cream",{"trials":1351,"activeCount":12},[],{"trials":1353,"activeCount":12},[],{"trials":1355,"activeCount":12},[],{"trials":1357,"activeCount":12},[],{"intervention":1348,"totalTrials":119,"cells":1359},{"EARLY_PHASE1":1360,"PHASE1":1362,"PHASE2":1368,"PHASE3":1370,"PHASE4":1372,"NA":1374},{"trials":1361,"activeCount":12},[],{"trials":1363,"activeCount":12},[1364],{"nctId":1340,"briefTitle":1341,"status":112,"phases":1365,"primaryCompletion":1343,"completion":575,"start":1344,"enrollment":1345,"conditions":1366,"interventions":1367},[55],[27],[1333,1348,1349],{"trials":1369,"activeCount":12},[],{"trials":1371,"activeCount":12},[],{"trials":1373,"activeCount":12},[],{"trials":1375,"activeCount":12},[],{"intervention":1349,"totalTrials":119,"cells":1377},{"EARLY_PHASE1":1378,"PHASE1":1380,"PHASE2":1386,"PHASE3":1388,"PHASE4":1390,"NA":1392},{"trials":1379,"activeCount":12},[],{"trials":1381,"activeCount":12},[1382],{"nctId":1340,"briefTitle":1341,"status":112,"phases":1383,"primaryCompletion":1343,"completion":575,"start":1344,"enrollment":1345,"conditions":1384,"interventions":1385},[55],[27],[1333,1348,1349],{"trials":1387,"activeCount":12},[],{"trials":1389,"activeCount":12},[],{"trials":1391,"activeCount":12},[],{"trials":1393,"activeCount":12},[],{"intervention":1395,"totalTrials":119,"cells":1396},"Clindamycin Phosphate",{"EARLY_PHASE1":1397,"PHASE1":1399,"PHASE2":1413,"PHASE3":1415,"PHASE4":1417,"NA":1419},{"trials":1398,"activeCount":12},[],{"trials":1400,"activeCount":12},[1401],{"nctId":1402,"briefTitle":1403,"status":112,"phases":1404,"primaryCompletion":1405,"completion":1406,"start":1407,"enrollment":1408,"conditions":1409,"interventions":1410},"NCT04321070","Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris",[55],"2019-12-14","2020-03-06","2019-09-09",550,[15],[1395,1411,1412],"Clindamycin Phosphate RLD","Placebos",{"trials":1414,"activeCount":12},[],{"trials":1416,"activeCount":12},[],{"trials":1418,"activeCount":12},[],{"trials":1420,"activeCount":12},[],{"intervention":1411,"totalTrials":119,"cells":1422},{"EARLY_PHASE1":1423,"PHASE1":1425,"PHASE2":1431,"PHASE3":1433,"PHASE4":1435,"NA":1437},{"trials":1424,"activeCount":12},[],{"trials":1426,"activeCount":12},[1427],{"nctId":1402,"briefTitle":1403,"status":112,"phases":1428,"primaryCompletion":1405,"completion":1406,"start":1407,"enrollment":1408,"conditions":1429,"interventions":1430},[55],[15],[1395,1411,1412],{"trials":1432,"activeCount":12},[],{"trials":1434,"activeCount":12},[],{"trials":1436,"activeCount":12},[],{"trials":1438,"activeCount":12},[],{"intervention":1412,"totalTrials":119,"cells":1440},{"EARLY_PHASE1":1441,"PHASE1":1443,"PHASE2":1449,"PHASE3":1451,"PHASE4":1453,"NA":1455},{"trials":1442,"activeCount":12},[],{"trials":1444,"activeCount":12},[1445],{"nctId":1402,"briefTitle":1403,"status":112,"phases":1446,"primaryCompletion":1405,"completion":1406,"start":1407,"enrollment":1408,"conditions":1447,"interventions":1448},[55],[15],[1395,1411,1412],{"trials":1450,"activeCount":12},[],{"trials":1452,"activeCount":12},[],{"trials":1454,"activeCount":12},[],{"trials":1456,"activeCount":12},[],{"intervention":1458,"totalTrials":119,"cells":1459},"Metronidazole Topical Gel 1%",{"EARLY_PHASE1":1460,"PHASE1":1462,"PHASE2":1473,"PHASE3":1475,"PHASE4":1477,"NA":1479},{"trials":1461,"activeCount":12},[],{"trials":1463,"activeCount":12},[1464],{"nctId":1465,"briefTitle":1466,"status":112,"phases":1467,"primaryCompletion":1468,"completion":1469,"start":519,"enrollment":1470,"conditions":1471,"interventions":1472},"NCT01513863","A Therapeutic Equivalence Study of Two Metronidazole 1%Topical Gel Treatments for Patients With Rosacea",[55],"2012-06","2012-09",602,[863],[1458,1458],{"trials":1474,"activeCount":12},[],{"trials":1476,"activeCount":12},[],{"trials":1478,"activeCount":12},[],{"trials":1480,"activeCount":12},[],{"intervention":1482,"totalTrials":119,"cells":1483},"Oxiconazole Nitrate Cream 1%",{"EARLY_PHASE1":1484,"PHASE1":1486,"PHASE2":1497,"PHASE3":1499,"PHASE4":1501,"NA":1503},{"trials":1485,"activeCount":12},[],{"trials":1487,"activeCount":12},[1488],{"nctId":1489,"briefTitle":1490,"status":112,"phases":1491,"primaryCompletion":1492,"completion":576,"start":1493,"enrollment":1494,"conditions":1495,"interventions":1496},"NCT01519752","A Therapeutic Equivalence Study of Two Oxiconazole Nitrate Topical Cream Treatments for Patients With Tinea Pedis",[55],"2012-08","2011-11",661,[21],[1482,1482],{"trials":1498,"activeCount":12},[],{"trials":1500,"activeCount":12},[],{"trials":1502,"activeCount":12},[],{"trials":1504,"activeCount":12},[],{"intervention":865,"totalTrials":119,"cells":1506},{"EARLY_PHASE1":1507,"PHASE1":1509,"PHASE2":1515,"PHASE3":1517,"PHASE4":1519,"NA":1521},{"trials":1508,"activeCount":12},[],{"trials":1510,"activeCount":12},[1511],{"nctId":856,"briefTitle":857,"status":112,"phases":1512,"primaryCompletion":859,"completion":860,"start":286,"enrollment":861,"conditions":1513,"interventions":1514},[55],[863],[865,866,814],{"trials":1516,"activeCount":12},[],{"trials":1518,"activeCount":12},[],{"trials":1520,"activeCount":12},[],{"trials":1522,"activeCount":12},[],{"intervention":866,"totalTrials":119,"cells":1524},{"EARLY_PHASE1":1525,"PHASE1":1527,"PHASE2":1533,"PHASE3":1535,"PHASE4":1537,"NA":1539},{"trials":1526,"activeCount":12},[],{"trials":1528,"activeCount":12},[1529],{"nctId":856,"briefTitle":857,"status":112,"phases":1530,"primaryCompletion":859,"completion":860,"start":286,"enrollment":861,"conditions":1531,"interventions":1532},[55],[863],[865,866,814],{"trials":1534,"activeCount":12},[],{"trials":1536,"activeCount":12},[],{"trials":1538,"activeCount":12},[],{"trials":1540,"activeCount":12},[],{"intervention":1542,"totalTrials":119,"cells":1543},"Test.",{"EARLY_PHASE1":1544,"PHASE1":1546,"PHASE2":1558,"PHASE3":1560,"PHASE4":1562,"NA":1564},{"trials":1545,"activeCount":12},[],{"trials":1547,"activeCount":12},[1548],{"nctId":1549,"briefTitle":1550,"status":112,"phases":1551,"primaryCompletion":1552,"completion":1552,"start":1553,"enrollment":1554,"conditions":1555,"interventions":1556},"NCT02929719","Study Comparing Test to Aczone 5% and Both to a Placebo Control in the Treatment of Acne Vulgaris",[55],"2016-06","2014-04",1134,[15],[1542,1557],"Aczone Gel 5%",{"trials":1559,"activeCount":12},[],{"trials":1561,"activeCount":12},[],{"trials":1563,"activeCount":12},[],{"trials":1565,"activeCount":12},[],{"intervention":1557,"totalTrials":119,"cells":1567},{"EARLY_PHASE1":1568,"PHASE1":1570,"PHASE2":1576,"PHASE3":1578,"PHASE4":1580,"NA":1582},{"trials":1569,"activeCount":12},[],{"trials":1571,"activeCount":12},[1572],{"nctId":1549,"briefTitle":1550,"status":112,"phases":1573,"primaryCompletion":1552,"completion":1552,"start":1553,"enrollment":1554,"conditions":1574,"interventions":1575},[55],[15],[1542,1557],{"trials":1577,"activeCount":12},[],{"trials":1579,"activeCount":12},[],{"trials":1581,"activeCount":12},[],{"trials":1583,"activeCount":12},[],{"intervention":1585,"totalTrials":119,"cells":1586},"Tretinoin Gel Microsphere, 0.04%",{"EARLY_PHASE1":1587,"PHASE1":1589,"PHASE2":1601,"PHASE3":1603,"PHASE4":1605,"NA":1607},{"trials":1588,"activeCount":12},[],{"trials":1590,"activeCount":12},[1591],{"nctId":1592,"briefTitle":1593,"status":112,"phases":1594,"primaryCompletion":1595,"completion":1595,"start":1596,"enrollment":1597,"conditions":1598,"interventions":1599},"NCT07469228","A Study Comparing Tretinoin Gel Microsphere, 0.04% and RETIN-A MICRO ® Gel Microsphere, 0.04% in the Treatment of Acne Vulgaris",[55],"2025-12-15","2025-08-04",1043,[15],[1585,1600],"RETIN-A MICRO® (Tretinoin) Gel Microsphere, 0.04%",{"trials":1602,"activeCount":12},[],{"trials":1604,"activeCount":12},[],{"trials":1606,"activeCount":12},[],{"trials":1608,"activeCount":12},[],{"intervention":1600,"totalTrials":119,"cells":1610},{"EARLY_PHASE1":1611,"PHASE1":1613,"PHASE2":1619,"PHASE3":1621,"PHASE4":1623,"NA":1625},{"trials":1612,"activeCount":12},[],{"trials":1614,"activeCount":12},[1615],{"nctId":1592,"briefTitle":1593,"status":112,"phases":1616,"primaryCompletion":1595,"completion":1595,"start":1596,"enrollment":1597,"conditions":1617,"interventions":1618},[55],[15],[1585,1600],{"trials":1620,"activeCount":12},[],{"trials":1622,"activeCount":12},[],{"trials":1624,"activeCount":12},[],{"trials":1626,"activeCount":12},[],{"intervention":1628,"totalTrials":119,"cells":1629},"Tacrolimus 0.1% manufactured by Taro",{"EARLY_PHASE1":1630,"PHASE1":1632,"PHASE2":1643,"PHASE3":1645,"PHASE4":1647,"NA":1649},{"trials":1631,"activeCount":12},[],{"trials":1633,"activeCount":12},[1634],{"nctId":1635,"briefTitle":1636,"status":112,"phases":1637,"primaryCompletion":761,"completion":255,"start":1244,"enrollment":1638,"conditions":1639,"interventions":1640},"NCT00833079","Bioequivalence of Two Tacrolimus 0.1% Topical Ointment Formulations in Patients With Atopic Dermatitis",[55],500,[33],[1628,1641,1642],"Protopic - Tacrolimus 0.1%","Tacrolimus Vehicle manufactured by Taro",{"trials":1644,"activeCount":12},[],{"trials":1646,"activeCount":12},[],{"trials":1648,"activeCount":12},[],{"trials":1650,"activeCount":12},[],{"intervention":1641,"totalTrials":119,"cells":1652},{"EARLY_PHASE1":1653,"PHASE1":1655,"PHASE2":1661,"PHASE3":1663,"PHASE4":1665,"NA":1667},{"trials":1654,"activeCount":12},[],{"trials":1656,"activeCount":12},[1657],{"nctId":1635,"briefTitle":1636,"status":112,"phases":1658,"primaryCompletion":761,"completion":255,"start":1244,"enrollment":1638,"conditions":1659,"interventions":1660},[55],[33],[1628,1641,1642],{"trials":1662,"activeCount":12},[],{"trials":1664,"activeCount":12},[],{"trials":1666,"activeCount":12},[],{"trials":1668,"activeCount":12},[],{"intervention":1642,"totalTrials":119,"cells":1670},{"EARLY_PHASE1":1671,"PHASE1":1673,"PHASE2":1679,"PHASE3":1681,"PHASE4":1683,"NA":1685},{"trials":1672,"activeCount":12},[],{"trials":1674,"activeCount":12},[1675],{"nctId":1635,"briefTitle":1636,"status":112,"phases":1676,"primaryCompletion":761,"completion":255,"start":1244,"enrollment":1638,"conditions":1677,"interventions":1678},[55],[33],[1628,1641,1642],{"trials":1680,"activeCount":12},[],{"trials":1682,"activeCount":12},[],{"trials":1684,"activeCount":12},[],{"trials":1686,"activeCount":12},[],{"intervention":1688,"totalTrials":119,"cells":1689},"Tazarotene Cream 0.1%",{"EARLY_PHASE1":1690,"PHASE1":1692,"PHASE2":1704,"PHASE3":1706,"PHASE4":1708,"NA":1710},{"trials":1691,"activeCount":12},[],{"trials":1693,"activeCount":12},[1694],{"nctId":1695,"briefTitle":1696,"status":112,"phases":1697,"primaryCompletion":1010,"completion":1698,"start":1699,"enrollment":1700,"conditions":1701,"interventions":1702},"NCT02411955","A Study Comparing Tazarotene Cream 0.1% to Tazorac® and Both to a Placebo Control in the Treatment of Acne Vulgaris",[55],"2015-02","2014-06",1077,[15],[1688,1703],"Tazorac®",{"trials":1705,"activeCount":12},[],{"trials":1707,"activeCount":12},[],{"trials":1709,"activeCount":12},[],{"trials":1711,"activeCount":12},[],{"intervention":1703,"totalTrials":119,"cells":1713},{"EARLY_PHASE1":1714,"PHASE1":1716,"PHASE2":1722,"PHASE3":1724,"PHASE4":1726,"NA":1728},{"trials":1715,"activeCount":12},[],{"trials":1717,"activeCount":12},[1718],{"nctId":1695,"briefTitle":1696,"status":112,"phases":1719,"primaryCompletion":1010,"completion":1698,"start":1699,"enrollment":1700,"conditions":1720,"interventions":1721},[55],[15],[1688,1703],{"trials":1723,"activeCount":12},[],{"trials":1725,"activeCount":12},[],{"trials":1727,"activeCount":12},[],{"trials":1729,"activeCount":12},[],{"intervention":891,"totalTrials":119,"cells":1731},{"EARLY_PHASE1":1732,"PHASE1":1734,"PHASE2":1740,"PHASE3":1742,"PHASE4":1744,"NA":1746},{"trials":1733,"activeCount":12},[],{"trials":1735,"activeCount":12},[1736],{"nctId":883,"briefTitle":884,"status":112,"phases":1737,"primaryCompletion":886,"completion":886,"start":887,"enrollment":888,"conditions":1738,"interventions":1739},[55],[15],[876,891],{"trials":1741,"activeCount":12},[],{"trials":1743,"activeCount":12},[],{"trials":1745,"activeCount":12},[],{"trials":1747,"activeCount":12},[],{"intervention":1749,"totalTrials":119,"cells":1750},"Adapalene and Benzoyl Peroxide Gel 0.1%\u002F2.5%",{"EARLY_PHASE1":1751,"PHASE1":1753,"PHASE2":1764,"PHASE3":1766,"PHASE4":1768,"NA":1770},{"trials":1752,"activeCount":12},[],{"trials":1754,"activeCount":12},[1755],{"nctId":1756,"briefTitle":1757,"status":112,"phases":1758,"primaryCompletion":1051,"completion":1052,"start":1759,"enrollment":1760,"conditions":1761,"interventions":1762},"NCT01742637","Study Comparing Adapalene and Benzoyl Peroxide Gel 0.1%\u002F2.5% to Epiduo® and Both to a Placebo Control in the Treatment of Acne Vulgaris",[55],"2012-10",2008,[15],[1749,1763],"Epiduo® Gel",{"trials":1765,"activeCount":12},[],{"trials":1767,"activeCount":12},[],{"trials":1769,"activeCount":12},[],{"trials":1771,"activeCount":12},[],{"intervention":1763,"totalTrials":119,"cells":1773},{"EARLY_PHASE1":1774,"PHASE1":1776,"PHASE2":1782,"PHASE3":1784,"PHASE4":1786,"NA":1788},{"trials":1775,"activeCount":12},[],{"trials":1777,"activeCount":12},[1778],{"nctId":1756,"briefTitle":1757,"status":112,"phases":1779,"primaryCompletion":1051,"completion":1052,"start":1759,"enrollment":1760,"conditions":1780,"interventions":1781},[55],[15],[1749,1763],{"trials":1783,"activeCount":12},[],{"trials":1785,"activeCount":12},[],{"trials":1787,"activeCount":12},[],{"trials":1789,"activeCount":12},[],{"intervention":1791,"totalTrials":119,"cells":1792},"Naftifine Hydrochloride Gel 2%",{"EARLY_PHASE1":1793,"PHASE1":1795,"PHASE2":1807,"PHASE3":1809,"PHASE4":1811,"NA":1813},{"trials":1794,"activeCount":12},[],{"trials":1796,"activeCount":12},[1797],{"nctId":1798,"briefTitle":1799,"status":112,"phases":1800,"primaryCompletion":1801,"completion":1801,"start":1802,"enrollment":1803,"conditions":1804,"interventions":1805},"NCT02335255","Evaluate Safety and Efficacy of Naftifine Hydrochloride Gel 2% and Naftin® Gel 2% in Tinea Pedis",[55],"2018-05-15","2014-06-27",1519,[21],[1791,1806],"Naftin® Gel 2%",{"trials":1808,"activeCount":12},[],{"trials":1810,"activeCount":12},[],{"trials":1812,"activeCount":12},[],{"trials":1814,"activeCount":12},[],{"intervention":1806,"totalTrials":119,"cells":1816},{"EARLY_PHASE1":1817,"PHASE1":1819,"PHASE2":1825,"PHASE3":1827,"PHASE4":1829,"NA":1831},{"trials":1818,"activeCount":12},[],{"trials":1820,"activeCount":12},[1821],{"nctId":1798,"briefTitle":1799,"status":112,"phases":1822,"primaryCompletion":1801,"completion":1801,"start":1802,"enrollment":1803,"conditions":1823,"interventions":1824},[55],[21],[1791,1806],{"trials":1826,"activeCount":12},[],{"trials":1828,"activeCount":12},[],{"trials":1830,"activeCount":12},[],{"trials":1832,"activeCount":12},[],{"intervention":1834,"totalTrials":119,"cells":1835},"Ketoconazole Shampoo, 2%",{"EARLY_PHASE1":1836,"PHASE1":1838,"PHASE2":1850,"PHASE3":1852,"PHASE4":1854,"NA":1856},{"trials":1837,"activeCount":12},[],{"trials":1839,"activeCount":12},[1840],{"nctId":1841,"briefTitle":1842,"status":112,"phases":1843,"primaryCompletion":1844,"completion":1844,"start":1845,"enrollment":1846,"conditions":1847,"interventions":1849},"NCT06305637","A Study Comparing Ketoconazole Shampoo, 2% and Ketoconazole 2% Shampoo (RS) in the Treatment of Tinea Versicolor.",[55],"2024-02-10","2023-12-04",430,[1848],"Tinea Versicolor",[1834,1834],{"trials":1851,"activeCount":12},[],{"trials":1853,"activeCount":12},[],{"trials":1855,"activeCount":12},[],{"trials":1857,"activeCount":12},[],{"intervention":1859,"totalTrials":119,"cells":1860},"Clindamycin and Benzoyl Peroxide Gel 1.2%\u002F3.75%",{"EARLY_PHASE1":1861,"PHASE1":1863,"PHASE2":1874,"PHASE3":1876,"PHASE4":1878,"NA":1880},{"trials":1862,"activeCount":12},[],{"trials":1864,"activeCount":12},[1865],{"nctId":1866,"briefTitle":1867,"status":112,"phases":1868,"primaryCompletion":1869,"completion":1139,"start":739,"enrollment":1870,"conditions":1871,"interventions":1872},"NCT02578043","A Study Comparing Clindamycin and Benzoyl Peroxide Gel 1.2%\u002F3.75% to Onexton™ Gel in the Treatment of Acne Vulgaris",[55],"2015-08",844,[15],[1859,1873],"Onexton™ Gel",{"trials":1875,"activeCount":12},[],{"trials":1877,"activeCount":12},[],{"trials":1879,"activeCount":12},[],{"trials":1881,"activeCount":12},[],{"intervention":1873,"totalTrials":119,"cells":1883},{"EARLY_PHASE1":1884,"PHASE1":1886,"PHASE2":1892,"PHASE3":1894,"PHASE4":1896,"NA":1898},{"trials":1885,"activeCount":12},[],{"trials":1887,"activeCount":12},[1888],{"nctId":1866,"briefTitle":1867,"status":112,"phases":1889,"primaryCompletion":1869,"completion":1139,"start":739,"enrollment":1870,"conditions":1890,"interventions":1891},[55],[15],[1859,1873],{"trials":1893,"activeCount":12},[],{"trials":1895,"activeCount":12},[],{"trials":1897,"activeCount":12},[],{"trials":1899,"activeCount":12},[],{"intervention":1901,"totalTrials":119,"cells":1902},"Oxymetazoline hydrochloride Cream, 1%",{"EARLY_PHASE1":1903,"PHASE1":1905,"PHASE2":1919,"PHASE3":1921,"PHASE4":1923,"NA":1925},{"trials":1904,"activeCount":12},[],{"trials":1906,"activeCount":12},[1907],{"nctId":1908,"briefTitle":1909,"status":112,"phases":1910,"primaryCompletion":1911,"completion":1912,"start":1913,"enrollment":1914,"conditions":1915,"interventions":1917},"NCT05148689","A Study Comparing Oxymetazoline 1% Cream to RHOFADE",[55],"2019-03-21","2019-05-31","2018-02-23",82,[1916],"Bioequivalence",[1901,1918],"Rhofade™ (oxymetazoline) cream, 1%",{"trials":1920,"activeCount":12},[],{"trials":1922,"activeCount":12},[],{"trials":1924,"activeCount":12},[],{"trials":1926,"activeCount":12},[],{"intervention":1918,"totalTrials":119,"cells":1928},{"EARLY_PHASE1":1929,"PHASE1":1931,"PHASE2":1937,"PHASE3":1939,"PHASE4":1941,"NA":1943},{"trials":1930,"activeCount":12},[],{"trials":1932,"activeCount":12},[1933],{"nctId":1908,"briefTitle":1909,"status":112,"phases":1934,"primaryCompletion":1911,"completion":1912,"start":1913,"enrollment":1914,"conditions":1935,"interventions":1936},[55],[1916],[1901,1918],{"trials":1938,"activeCount":12},[],{"trials":1940,"activeCount":12},[],{"trials":1942,"activeCount":12},[],{"trials":1944,"activeCount":12},[],{"intervention":1946,"totalTrials":119,"cells":1947},"Ruxolitinib Topical Cream 1.5%",{"EARLY_PHASE1":1948,"PHASE1":1950,"PHASE2":1962,"PHASE3":1964,"PHASE4":1966,"NA":1968},{"trials":1949,"activeCount":12},[],{"trials":1951,"activeCount":12},[1952],{"nctId":1953,"briefTitle":1954,"status":112,"phases":1955,"primaryCompletion":1956,"completion":1956,"start":1957,"enrollment":1958,"conditions":1959,"interventions":1960},"NCT06673654","A Study, Comparing Ruxolitinib Topical Cream 1.5% (Taro Pharmaceuticals U.S.A, Inc.) to OPZELURA (Ruxolitinib) Cream for the Treatment of Mild-to-Moderate Atopic Dermatitis.",[55],"2024-09-23","2023-08-11",476,[33],[1946,1961],"OPZELURA (Ruxolitinib) Cream",{"trials":1963,"activeCount":12},[],{"trials":1965,"activeCount":12},[],{"trials":1967,"activeCount":12},[],{"trials":1969,"activeCount":12},[],{"intervention":1961,"totalTrials":119,"cells":1971},{"EARLY_PHASE1":1972,"PHASE1":1974,"PHASE2":1980,"PHASE3":1982,"PHASE4":1984,"NA":1986},{"trials":1973,"activeCount":12},[],{"trials":1975,"activeCount":12},[1976],{"nctId":1953,"briefTitle":1954,"status":112,"phases":1977,"primaryCompletion":1956,"completion":1956,"start":1957,"enrollment":1958,"conditions":1978,"interventions":1979},[55],[33],[1946,1961],{"trials":1981,"activeCount":12},[],{"trials":1983,"activeCount":12},[],{"trials":1985,"activeCount":12},[],{"trials":1987,"activeCount":12},[],{"intervention":900,"totalTrials":119,"cells":1989},{"EARLY_PHASE1":1990,"PHASE1":1992,"PHASE2":1998,"PHASE3":2000,"PHASE4":2002,"NA":2004},{"trials":1991,"activeCount":12},[],{"trials":1993,"activeCount":12},[1994],{"nctId":893,"briefTitle":894,"status":112,"phases":1995,"primaryCompletion":896,"completion":897,"start":896,"enrollment":105,"conditions":1996,"interventions":1997},[55],[15],[876,900,901],{"trials":1999,"activeCount":12},[],{"trials":2001,"activeCount":12},[],{"trials":2003,"activeCount":12},[],{"trials":2005,"activeCount":12},[],{"intervention":901,"totalTrials":119,"cells":2007},{"EARLY_PHASE1":2008,"PHASE1":2010,"PHASE2":2016,"PHASE3":2018,"PHASE4":2020,"NA":2022},{"trials":2009,"activeCount":12},[],{"trials":2011,"activeCount":12},[2012],{"nctId":893,"briefTitle":894,"status":112,"phases":2013,"primaryCompletion":896,"completion":897,"start":896,"enrollment":105,"conditions":2014,"interventions":2015},[55],[15],[876,900,901],{"trials":2017,"activeCount":12},[],{"trials":2019,"activeCount":12},[],{"trials":2021,"activeCount":12},[],{"trials":2023,"activeCount":12},[],{"intervention":2025,"totalTrials":119,"cells":2026},"CLPG Topical Gel 1%",{"EARLY_PHASE1":2027,"PHASE1":2029,"PHASE2":2041,"PHASE3":2043,"PHASE4":2045,"NA":2047},{"trials":2028,"activeCount":12},[],{"trials":2030,"activeCount":12},[2031],{"nctId":2032,"briefTitle":1403,"status":112,"phases":2033,"primaryCompletion":2034,"completion":2035,"start":2036,"enrollment":2037,"conditions":2038,"interventions":2039},"NCT04134273",[55],"2019-09-17","2019-10-15","2019-03-20",1260,[15],[2025,2040],"Clindamycin",{"trials":2042,"activeCount":12},[],{"trials":2044,"activeCount":12},[],{"trials":2046,"activeCount":12},[],{"trials":2048,"activeCount":12},[],{"intervention":2040,"totalTrials":119,"cells":2050},{"EARLY_PHASE1":2051,"PHASE1":2053,"PHASE2":2059,"PHASE3":2061,"PHASE4":2063,"NA":2065},{"trials":2052,"activeCount":12},[],{"trials":2054,"activeCount":12},[2055],{"nctId":2032,"briefTitle":1403,"status":112,"phases":2056,"primaryCompletion":2034,"completion":2035,"start":2036,"enrollment":2037,"conditions":2057,"interventions":2058},[55],[15],[2025,2040],{"trials":2060,"activeCount":12},[],{"trials":2062,"activeCount":12},[],{"trials":2064,"activeCount":12},[],{"trials":2066,"activeCount":12},[],{"intervention":2068,"totalTrials":119,"cells":2069},"Clocortolone Pivalate",{"EARLY_PHASE1":2070,"PHASE1":2072,"PHASE2":2084,"PHASE3":2086,"PHASE4":2088,"NA":2090},{"trials":2071,"activeCount":12},[],{"trials":2073,"activeCount":12},[2074],{"nctId":2075,"briefTitle":2076,"status":112,"phases":2077,"primaryCompletion":2078,"completion":2079,"start":2080,"enrollment":206,"conditions":2081,"interventions":2083},"NCT04358770","Bio-equivalence Vasoconstriction Activity Study for Topically Applied Clocortolone Pivalate 0.1% Cream",[55],"2018-04-27","2018-05-11","2018-03-02",[2082],"Bioequivalence Study",[2068],{"trials":2085,"activeCount":12},[],{"trials":2087,"activeCount":12},[],{"trials":2089,"activeCount":12},[],{"trials":2091,"activeCount":12},[],{"intervention":2093,"totalTrials":119,"cells":2094},"Diclofenac Sodium Gel 3%",{"EARLY_PHASE1":2095,"PHASE1":2097,"PHASE2":2108,"PHASE3":2110,"PHASE4":2112,"NA":2114},{"trials":2096,"activeCount":12},[],{"trials":2098,"activeCount":12},[2099],{"nctId":2100,"briefTitle":2101,"status":112,"phases":2102,"primaryCompletion":965,"completion":1343,"start":1759,"enrollment":2103,"conditions":2104,"interventions":2105},"NCT01742663","A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® Gel 3% in the Treatment of Actinic Keratosis",[55],435,[27],[2093,2106,2107],"Solaraze® (diclofenac sodium) Gel 3%","Vehicle Topical Gel",{"trials":2109,"activeCount":12},[],{"trials":2111,"activeCount":12},[],{"trials":2113,"activeCount":12},[],{"trials":2115,"activeCount":12},[],{"intervention":2106,"totalTrials":119,"cells":2117},{"EARLY_PHASE1":2118,"PHASE1":2120,"PHASE2":2126,"PHASE3":2128,"PHASE4":2130,"NA":2132},{"trials":2119,"activeCount":12},[],{"trials":2121,"activeCount":12},[2122],{"nctId":2100,"briefTitle":2101,"status":112,"phases":2123,"primaryCompletion":965,"completion":1343,"start":1759,"enrollment":2103,"conditions":2124,"interventions":2125},[55],[27],[2093,2106,2107],{"trials":2127,"activeCount":12},[],{"trials":2129,"activeCount":12},[],{"trials":2131,"activeCount":12},[],{"trials":2133,"activeCount":12},[],{"intervention":2107,"totalTrials":119,"cells":2135},{"EARLY_PHASE1":2136,"PHASE1":2138,"PHASE2":2144,"PHASE3":2146,"PHASE4":2148,"NA":2150},{"trials":2137,"activeCount":12},[],{"trials":2139,"activeCount":12},[2140],{"nctId":2100,"briefTitle":2101,"status":112,"phases":2141,"primaryCompletion":965,"completion":1343,"start":1759,"enrollment":2103,"conditions":2142,"interventions":2143},[55],[27],[2093,2106,2107],{"trials":2145,"activeCount":12},[],{"trials":2147,"activeCount":12},[],{"trials":2149,"activeCount":12},[],{"trials":2151,"activeCount":12},[],{"intervention":2153,"totalTrials":119,"cells":2154},"Butenafine Hydrochloride Cream, 1%",{"EARLY_PHASE1":2155,"PHASE1":2157,"PHASE2":2169,"PHASE3":2171,"PHASE4":2173,"NA":2175},{"trials":2156,"activeCount":12},[],{"trials":2158,"activeCount":12},[2159],{"nctId":2160,"briefTitle":2161,"status":112,"phases":2162,"primaryCompletion":1492,"completion":2163,"start":477,"enrollment":2164,"conditions":2165,"interventions":2166},"NCT01580878","Evaluate the Safety & Bioequivalence of a Generic Butenafine Cream & Lotrimin Ultra® & Compare Both to a Vehicle Control in Treatment of Interdigital Tinea Pedis",[55],"2012-12",707,[21],[2153,2167,2168],"Lotrimin Ultra®","Butenafine Vehicle",{"trials":2170,"activeCount":12},[],{"trials":2172,"activeCount":12},[],{"trials":2174,"activeCount":12},[],{"trials":2176,"activeCount":12},[],{"intervention":2167,"totalTrials":119,"cells":2178},{"EARLY_PHASE1":2179,"PHASE1":2181,"PHASE2":2187,"PHASE3":2189,"PHASE4":2191,"NA":2193},{"trials":2180,"activeCount":12},[],{"trials":2182,"activeCount":12},[2183],{"nctId":2160,"briefTitle":2161,"status":112,"phases":2184,"primaryCompletion":1492,"completion":2163,"start":477,"enrollment":2164,"conditions":2185,"interventions":2186},[55],[21],[2153,2167,2168],{"trials":2188,"activeCount":12},[],{"trials":2190,"activeCount":12},[],{"trials":2192,"activeCount":12},[],{"trials":2194,"activeCount":12},[],{"intervention":2168,"totalTrials":119,"cells":2196},{"EARLY_PHASE1":2197,"PHASE1":2199,"PHASE2":2205,"PHASE3":2207,"PHASE4":2209,"NA":2211},{"trials":2198,"activeCount":12},[],{"trials":2200,"activeCount":12},[2201],{"nctId":2160,"briefTitle":2161,"status":112,"phases":2202,"primaryCompletion":1492,"completion":2163,"start":477,"enrollment":2164,"conditions":2203,"interventions":2204},[55],[21],[2153,2167,2168],{"trials":2206,"activeCount":12},[],{"trials":2208,"activeCount":12},[],{"trials":2210,"activeCount":12},[],{"trials":2212,"activeCount":12},[],{"intervention":580,"totalTrials":119,"cells":2214},{"EARLY_PHASE1":2215,"PHASE1":2217,"PHASE2":2223,"PHASE3":2225,"PHASE4":2227,"NA":2229},{"trials":2216,"activeCount":12},[],{"trials":2218,"activeCount":12},[2219],{"nctId":571,"briefTitle":572,"status":112,"phases":2220,"primaryCompletion":574,"completion":575,"start":576,"enrollment":577,"conditions":2221,"interventions":2222},[55],[15],[580,581,564],{"trials":2224,"activeCount":12},[],{"trials":2226,"activeCount":12},[],{"trials":2228,"activeCount":12},[],{"trials":2230,"activeCount":12},[],{"intervention":581,"totalTrials":119,"cells":2232},{"EARLY_PHASE1":2233,"PHASE1":2235,"PHASE2":2241,"PHASE3":2243,"PHASE4":2245,"NA":2247},{"trials":2234,"activeCount":12},[],{"trials":2236,"activeCount":12},[2237],{"nctId":571,"briefTitle":572,"status":112,"phases":2238,"primaryCompletion":574,"completion":575,"start":576,"enrollment":577,"conditions":2239,"interventions":2240},[55],[15],[580,581,564],{"trials":2242,"activeCount":12},[],{"trials":2244,"activeCount":12},[],{"trials":2246,"activeCount":12},[],{"trials":2248,"activeCount":12},[],{"intervention":2250,"totalTrials":119,"cells":2251},"Tapinarof Cream, 1%",{"EARLY_PHASE1":2252,"PHASE1":2254,"PHASE2":2266,"PHASE3":2268,"PHASE4":2270,"NA":2272},{"trials":2253,"activeCount":12},[],{"trials":2255,"activeCount":12},[2256],{"nctId":2257,"briefTitle":2258,"status":112,"phases":2259,"primaryCompletion":2260,"completion":2260,"start":2261,"enrollment":2262,"conditions":2263,"interventions":2264},"NCT07546214","A Study Comparing Tapinarof Cream 1% and Vtama® Cream 1% in the Treatment of Plaque Psoriasis.",[55],"2026-03-18","2025-10-13",575,[18],[2250,2265],"Vtama® (Tapinarof) Cream, 1%",{"trials":2267,"activeCount":12},[],{"trials":2269,"activeCount":12},[],{"trials":2271,"activeCount":12},[],{"trials":2273,"activeCount":12},[],{"intervention":2265,"totalTrials":119,"cells":2275},{"EARLY_PHASE1":2276,"PHASE1":2278,"PHASE2":2284,"PHASE3":2286,"PHASE4":2288,"NA":2290},{"trials":2277,"activeCount":12},[],{"trials":2279,"activeCount":12},[2280],{"nctId":2257,"briefTitle":2258,"status":112,"phases":2281,"primaryCompletion":2260,"completion":2260,"start":2261,"enrollment":2262,"conditions":2282,"interventions":2283},[55],[18],[2250,2265],{"trials":2285,"activeCount":12},[],{"trials":2287,"activeCount":12},[],{"trials":2289,"activeCount":12},[],{"trials":2291,"activeCount":12},[],{"intervention":2293,"totalTrials":119,"cells":2294},"Butenafine Hydrochloride 1%",{"EARLY_PHASE1":2295,"PHASE1":2297,"PHASE2":2313,"PHASE3":2315,"PHASE4":2317,"NA":2319},{"trials":2296,"activeCount":12},[],{"trials":2298,"activeCount":12},[2299],{"nctId":2300,"briefTitle":2301,"status":329,"phases":2302,"primaryCompletion":2303,"completion":2304,"start":2305,"enrollment":2306,"conditions":2307,"interventions":2309},"NCT01119742","Clinical Equivalence of Two Generic Butenafine Hydrochloride 1% Creams as Compared to Lotrimin Ultra Cream in Patients With Interdigital Tinea Pedis",[55],"2011-03","2011-07","2010-07",428,[2308],"Interdigital Tinea Pedis",[2293,2310,2293,2311,2312],"Butenafine Hydrochloride 1% B","Vehicle A","Vehicle B",{"trials":2314,"activeCount":12},[],{"trials":2316,"activeCount":12},[],{"trials":2318,"activeCount":12},[],{"trials":2320,"activeCount":12},[],{"intervention":2310,"totalTrials":119,"cells":2322},{"EARLY_PHASE1":2323,"PHASE1":2325,"PHASE2":2331,"PHASE3":2333,"PHASE4":2335,"NA":2337},{"trials":2324,"activeCount":12},[],{"trials":2326,"activeCount":12},[2327],{"nctId":2300,"briefTitle":2301,"status":329,"phases":2328,"primaryCompletion":2303,"completion":2304,"start":2305,"enrollment":2306,"conditions":2329,"interventions":2330},[55],[2308],[2293,2310,2293,2311,2312],{"trials":2332,"activeCount":12},[],{"trials":2334,"activeCount":12},[],{"trials":2336,"activeCount":12},[],{"trials":2338,"activeCount":12},[],{"intervention":2311,"totalTrials":119,"cells":2340},{"EARLY_PHASE1":2341,"PHASE1":2343,"PHASE2":2349,"PHASE3":2351,"PHASE4":2353,"NA":2355},{"trials":2342,"activeCount":12},[],{"trials":2344,"activeCount":12},[2345],{"nctId":2300,"briefTitle":2301,"status":329,"phases":2346,"primaryCompletion":2303,"completion":2304,"start":2305,"enrollment":2306,"conditions":2347,"interventions":2348},[55],[2308],[2293,2310,2293,2311,2312],{"trials":2350,"activeCount":12},[],{"trials":2352,"activeCount":12},[],{"trials":2354,"activeCount":12},[],{"trials":2356,"activeCount":12},[],{"intervention":2312,"totalTrials":119,"cells":2358},{"EARLY_PHASE1":2359,"PHASE1":2361,"PHASE2":2367,"PHASE3":2369,"PHASE4":2371,"NA":2373},{"trials":2360,"activeCount":12},[],{"trials":2362,"activeCount":12},[2363],{"nctId":2300,"briefTitle":2301,"status":329,"phases":2364,"primaryCompletion":2303,"completion":2304,"start":2305,"enrollment":2306,"conditions":2365,"interventions":2366},[55],[2308],[2293,2310,2293,2311,2312],{"trials":2368,"activeCount":12},[],{"trials":2370,"activeCount":12},[],{"trials":2372,"activeCount":12},[],{"trials":2374,"activeCount":12},[],{"intervention":2376,"totalTrials":119,"cells":2377},"Adapalene Gel 0.3%",{"EARLY_PHASE1":2378,"PHASE1":2380,"PHASE2":2391,"PHASE3":2393,"PHASE4":2395,"NA":2397},{"trials":2379,"activeCount":12},[],{"trials":2381,"activeCount":12},[2382],{"nctId":2383,"briefTitle":2384,"status":112,"phases":2385,"primaryCompletion":1698,"completion":1698,"start":2386,"enrollment":2387,"conditions":2388,"interventions":2389},"NCT02411942","Study Comparing Adapalene Gel 0.3% to Differin® and Both to a Placebo Control in Treatment of Acne Vulgaris",[55],"2014-08",753,[15],[2376,2390],"Differin®",{"trials":2392,"activeCount":12},[],{"trials":2394,"activeCount":12},[],{"trials":2396,"activeCount":12},[],{"trials":2398,"activeCount":12},[],{"intervention":2390,"totalTrials":119,"cells":2400},{"EARLY_PHASE1":2401,"PHASE1":2403,"PHASE2":2409,"PHASE3":2411,"PHASE4":2413,"NA":2415},{"trials":2402,"activeCount":12},[],{"trials":2404,"activeCount":12},[2405],{"nctId":2383,"briefTitle":2384,"status":112,"phases":2406,"primaryCompletion":1698,"completion":1698,"start":2386,"enrollment":2387,"conditions":2407,"interventions":2408},[55],[15],[2376,2390],{"trials":2410,"activeCount":12},[],{"trials":2412,"activeCount":12},[],{"trials":2414,"activeCount":12},[],{"trials":2416,"activeCount":12},[],{"intervention":246,"totalTrials":119,"cells":2418},{"EARLY_PHASE1":2419,"PHASE1":2421,"PHASE2":2427,"PHASE3":2429,"PHASE4":2431,"NA":2433},{"trials":2420,"activeCount":12},[],{"trials":2422,"activeCount":12},[2423],{"nctId":239,"briefTitle":240,"status":112,"phases":2424,"primaryCompletion":242,"completion":242,"start":243,"enrollment":194,"conditions":2425,"interventions":2426},[55],[31],[232,246],{"trials":2428,"activeCount":12},[],{"trials":2430,"activeCount":12},[],{"trials":2432,"activeCount":12},[],{"trials":2434,"activeCount":12},[],{"intervention":2436,"totalTrials":119,"cells":2437},"Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2%",{"EARLY_PHASE1":2438,"PHASE1":2440,"PHASE2":2452,"PHASE3":2454,"PHASE4":2456,"NA":2458},{"trials":2439,"activeCount":12},[],{"trials":2441,"activeCount":12},[2442],{"nctId":2443,"briefTitle":2444,"status":112,"phases":2445,"primaryCompletion":2446,"completion":2446,"start":2447,"enrollment":2448,"conditions":2449,"interventions":2450},"NCT06673641","A Study Comparing Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2% (Taro Pharmaceuticals U.S.A., Inc.) and CABTREO Topical Gel for the Treatment of Acne Vulgaris.",[55],"2024-09-03","2024-05-13",382,[15],[2436,2451],"CABTREO Topical Gel",{"trials":2453,"activeCount":12},[],{"trials":2455,"activeCount":12},[],{"trials":2457,"activeCount":12},[],{"trials":2459,"activeCount":12},[],{"intervention":2451,"totalTrials":119,"cells":2461},{"EARLY_PHASE1":2462,"PHASE1":2464,"PHASE2":2470,"PHASE3":2472,"PHASE4":2474,"NA":2476},{"trials":2463,"activeCount":12},[],{"trials":2465,"activeCount":12},[2466],{"nctId":2443,"briefTitle":2444,"status":112,"phases":2467,"primaryCompletion":2446,"completion":2446,"start":2447,"enrollment":2448,"conditions":2468,"interventions":2469},[55],[15],[2436,2451],{"trials":2471,"activeCount":12},[],{"trials":2473,"activeCount":12},[],{"trials":2475,"activeCount":12},[],{"trials":2477,"activeCount":12},[],{"intervention":2479,"totalTrials":119,"cells":2480},"Imiquimod 5% manufactured by Taro",{"EARLY_PHASE1":2481,"PHASE1":2483,"PHASE2":2496,"PHASE3":2498,"PHASE4":2500,"NA":2502},{"trials":2482,"activeCount":12},[],{"trials":2484,"activeCount":12},[2485],{"nctId":2486,"briefTitle":2487,"status":112,"phases":2488,"primaryCompletion":2489,"completion":2490,"start":1246,"enrollment":2491,"conditions":2492,"interventions":2493},"NCT00828568","Bioequivalence Study of Two Imiquimod Cream 5%",[55],"2009-03","2009-05",425,[27],[2479,2494,2495],"Aldara - Imiquimod 5%","Imiquimod Vehicle manufactured by Taro",{"trials":2497,"activeCount":12},[],{"trials":2499,"activeCount":12},[],{"trials":2501,"activeCount":12},[],{"trials":2503,"activeCount":12},[],{"intervention":2494,"totalTrials":119,"cells":2505},{"EARLY_PHASE1":2506,"PHASE1":2508,"PHASE2":2514,"PHASE3":2516,"PHASE4":2518,"NA":2520},{"trials":2507,"activeCount":12},[],{"trials":2509,"activeCount":12},[2510],{"nctId":2486,"briefTitle":2487,"status":112,"phases":2511,"primaryCompletion":2489,"completion":2490,"start":1246,"enrollment":2491,"conditions":2512,"interventions":2513},[55],[27],[2479,2494,2495],{"trials":2515,"activeCount":12},[],{"trials":2517,"activeCount":12},[],{"trials":2519,"activeCount":12},[],{"trials":2521,"activeCount":12},[],{"intervention":2495,"totalTrials":119,"cells":2523},{"EARLY_PHASE1":2524,"PHASE1":2526,"PHASE2":2532,"PHASE3":2534,"PHASE4":2536,"NA":2538},{"trials":2525,"activeCount":12},[],{"trials":2527,"activeCount":12},[2528],{"nctId":2486,"briefTitle":2487,"status":112,"phases":2529,"primaryCompletion":2489,"completion":2490,"start":1246,"enrollment":2491,"conditions":2530,"interventions":2531},[55],[27],[2479,2494,2495],{"trials":2533,"activeCount":12},[],{"trials":2535,"activeCount":12},[],{"trials":2537,"activeCount":12},[],{"trials":2539,"activeCount":12},[],{"intervention":2541,"totalTrials":119,"cells":2542},"Clindamycin 1%\u002FBenzoyl Peroxide 5% Topical Gel",{"EARLY_PHASE1":2543,"PHASE1":2545,"PHASE2":2556,"PHASE3":2558,"PHASE4":2560,"NA":2562},{"trials":2544,"activeCount":12},[],{"trials":2546,"activeCount":12},[2547],{"nctId":2548,"briefTitle":2549,"status":112,"phases":2550,"primaryCompletion":2551,"completion":1053,"start":1469,"enrollment":2552,"conditions":2553,"interventions":2554},"NCT01769664","A Study Comparing Clindamycin 1%\u002FBenzoyl Peroxide 5% Topical Gel to Duac® Topical Gel in the Treatment of Acne Vulgaris",[55],"2013-06",650,[15],[2541,2555],"Duac® Topical Gel",{"trials":2557,"activeCount":12},[],{"trials":2559,"activeCount":12},[],{"trials":2561,"activeCount":12},[],{"trials":2563,"activeCount":12},[],{"intervention":2555,"totalTrials":119,"cells":2565},{"EARLY_PHASE1":2566,"PHASE1":2568,"PHASE2":2574,"PHASE3":2576,"PHASE4":2578,"NA":2580},{"trials":2567,"activeCount":12},[],{"trials":2569,"activeCount":12},[2570],{"nctId":2548,"briefTitle":2549,"status":112,"phases":2571,"primaryCompletion":2551,"completion":1053,"start":1469,"enrollment":2552,"conditions":2572,"interventions":2573},[55],[15],[2541,2555],{"trials":2575,"activeCount":12},[],{"trials":2577,"activeCount":12},[],{"trials":2579,"activeCount":12},[],{"trials":2581,"activeCount":12},[],{"intervention":2583,"totalTrials":119,"cells":2584},"DPSG 7.5%",{"EARLY_PHASE1":2585,"PHASE1":2587,"PHASE2":2600,"PHASE3":2602,"PHASE4":2604,"NA":2606},{"trials":2586,"activeCount":12},[],{"trials":2588,"activeCount":12},[2589],{"nctId":2590,"briefTitle":2591,"status":112,"phases":2592,"primaryCompletion":2593,"completion":2594,"start":2595,"enrollment":2596,"conditions":2597,"interventions":2598},"NCT03132194","Study Comparing Test to Aczone 7.5% and Both to a Placebo Control in the Treatment of Acne Vulgaris",[55],"2017-01-16","2017-01-30","2016-08-08",1125,[15],[2583,2599],"Aczone",{"trials":2601,"activeCount":12},[],{"trials":2603,"activeCount":12},[],{"trials":2605,"activeCount":12},[],{"trials":2607,"activeCount":12},[],{"intervention":2599,"totalTrials":119,"cells":2609},{"EARLY_PHASE1":2610,"PHASE1":2612,"PHASE2":2618,"PHASE3":2620,"PHASE4":2622,"NA":2624},{"trials":2611,"activeCount":12},[],{"trials":2613,"activeCount":12},[2614],{"nctId":2590,"briefTitle":2591,"status":112,"phases":2615,"primaryCompletion":2593,"completion":2594,"start":2595,"enrollment":2596,"conditions":2616,"interventions":2617},[55],[15],[2583,2599],{"trials":2619,"activeCount":12},[],{"trials":2621,"activeCount":12},[],{"trials":2623,"activeCount":12},[],{"trials":2625,"activeCount":12},[],{"intervention":2627,"totalTrials":119,"cells":2628},"Topical TA-102 A",{"EARLY_PHASE1":2629,"PHASE1":2631,"PHASE2":2647,"PHASE3":2649,"PHASE4":2651,"NA":2653},{"trials":2630,"activeCount":12},[],{"trials":2632,"activeCount":12},[2633],{"nctId":2634,"briefTitle":2635,"status":112,"phases":2636,"primaryCompletion":2637,"completion":2638,"start":2639,"enrollment":2640,"conditions":2641,"interventions":2642},"NCT03645499","An Open-Label Study to Assess Safety",[55],"2019-10-24","2020-01-07","2018-04-04",88,[18],[2627,2643,2644,2645,2646],"Topical TA-102 B","Topical TA-102 C","Topical TA-102 D","Topical TA-102 E",{"trials":2648,"activeCount":12},[],{"trials":2650,"activeCount":12},[],{"trials":2652,"activeCount":12},[],{"trials":2654,"activeCount":12},[],{"intervention":2643,"totalTrials":119,"cells":2656},{"EARLY_PHASE1":2657,"PHASE1":2659,"PHASE2":2665,"PHASE3":2667,"PHASE4":2669,"NA":2671},{"trials":2658,"activeCount":12},[],{"trials":2660,"activeCount":12},[2661],{"nctId":2634,"briefTitle":2635,"status":112,"phases":2662,"primaryCompletion":2637,"completion":2638,"start":2639,"enrollment":2640,"conditions":2663,"interventions":2664},[55],[18],[2627,2643,2644,2645,2646],{"trials":2666,"activeCount":12},[],{"trials":2668,"activeCount":12},[],{"trials":2670,"activeCount":12},[],{"trials":2672,"activeCount":12},[],{"intervention":2644,"totalTrials":119,"cells":2674},{"EARLY_PHASE1":2675,"PHASE1":2677,"PHASE2":2683,"PHASE3":2685,"PHASE4":2687,"NA":2689},{"trials":2676,"activeCount":12},[],{"trials":2678,"activeCount":12},[2679],{"nctId":2634,"briefTitle":2635,"status":112,"phases":2680,"primaryCompletion":2637,"completion":2638,"start":2639,"enrollment":2640,"conditions":2681,"interventions":2682},[55],[18],[2627,2643,2644,2645,2646],{"trials":2684,"activeCount":12},[],{"trials":2686,"activeCount":12},[],{"trials":2688,"activeCount":12},[],{"trials":2690,"activeCount":12},[],{"intervention":2645,"totalTrials":119,"cells":2692},{"EARLY_PHASE1":2693,"PHASE1":2695,"PHASE2":2701,"PHASE3":2703,"PHASE4":2705,"NA":2707},{"trials":2694,"activeCount":12},[],{"trials":2696,"activeCount":12},[2697],{"nctId":2634,"briefTitle":2635,"status":112,"phases":2698,"primaryCompletion":2637,"completion":2638,"start":2639,"enrollment":2640,"conditions":2699,"interventions":2700},[55],[18],[2627,2643,2644,2645,2646],{"trials":2702,"activeCount":12},[],{"trials":2704,"activeCount":12},[],{"trials":2706,"activeCount":12},[],{"trials":2708,"activeCount":12},[],{"intervention":2646,"totalTrials":119,"cells":2710},{"EARLY_PHASE1":2711,"PHASE1":2713,"PHASE2":2719,"PHASE3":2721,"PHASE4":2723,"NA":2725},{"trials":2712,"activeCount":12},[],{"trials":2714,"activeCount":12},[2715],{"nctId":2634,"briefTitle":2635,"status":112,"phases":2716,"primaryCompletion":2637,"completion":2638,"start":2639,"enrollment":2640,"conditions":2717,"interventions":2718},[55],[18],[2627,2643,2644,2645,2646],{"trials":2720,"activeCount":12},[],{"trials":2722,"activeCount":12},[],{"trials":2724,"activeCount":12},[],{"trials":2726,"activeCount":12},[],{"intervention":827,"totalTrials":119,"cells":2728},{"EARLY_PHASE1":2729,"PHASE1":2735,"PHASE2":2737,"PHASE3":2739,"PHASE4":2741,"NA":2743},{"trials":2730,"activeCount":12},[2731],{"nctId":819,"briefTitle":820,"status":112,"phases":2732,"primaryCompletion":822,"completion":822,"start":823,"enrollment":824,"conditions":2733,"interventions":2734},[54],[15],[827,828,814],{"trials":2736,"activeCount":12},[],{"trials":2738,"activeCount":12},[],{"trials":2740,"activeCount":12},[],{"trials":2742,"activeCount":12},[],{"trials":2744,"activeCount":12},[],{"intervention":828,"totalTrials":119,"cells":2746},{"EARLY_PHASE1":2747,"PHASE1":2753,"PHASE2":2755,"PHASE3":2757,"PHASE4":2759,"NA":2761},{"trials":2748,"activeCount":12},[2749],{"nctId":819,"briefTitle":820,"status":112,"phases":2750,"primaryCompletion":822,"completion":822,"start":823,"enrollment":824,"conditions":2751,"interventions":2752},[54],[15],[827,828,814],{"trials":2754,"activeCount":12},[],{"trials":2756,"activeCount":12},[],{"trials":2758,"activeCount":12},[],{"trials":2760,"activeCount":12},[],{"trials":2762,"activeCount":12},[],{"intervention":2764,"totalTrials":119,"cells":2765},"Tretinoin Gel Microsphere, 0.1%",{"EARLY_PHASE1":2766,"PHASE1":2778,"PHASE2":2780,"PHASE3":2782,"PHASE4":2784,"NA":2786},{"trials":2767,"activeCount":12},[2768],{"nctId":2769,"briefTitle":2770,"status":112,"phases":2771,"primaryCompletion":2772,"completion":2772,"start":2773,"enrollment":2774,"conditions":2775,"interventions":2776},"NCT04883736","A Study Comparing Tretinoin Gel Microsphere, 0.1% and RETIN-A MICRO ® Gel Microsphere, 0.1% in the Treatment of Acne Vulgaris",[54],"2021-04-16","2020-08-31",973,[15],[2764,2777],"RETIN-A MICRO® (Tretinoin) Gel Microsphere, 0.1%",{"trials":2779,"activeCount":12},[],{"trials":2781,"activeCount":12},[],{"trials":2783,"activeCount":12},[],{"trials":2785,"activeCount":12},[],{"trials":2787,"activeCount":12},[],{"intervention":2777,"totalTrials":119,"cells":2789},{"EARLY_PHASE1":2790,"PHASE1":2796,"PHASE2":2798,"PHASE3":2800,"PHASE4":2802,"NA":2804},{"trials":2791,"activeCount":12},[2792],{"nctId":2769,"briefTitle":2770,"status":112,"phases":2793,"primaryCompletion":2772,"completion":2772,"start":2773,"enrollment":2774,"conditions":2794,"interventions":2795},[54],[15],[2764,2777],{"trials":2797,"activeCount":12},[],{"trials":2799,"activeCount":12},[],{"trials":2801,"activeCount":12},[],{"trials":2803,"activeCount":12},[],{"trials":2805,"activeCount":12},[],{"intervention":2807,"totalTrials":119,"cells":2808},"Halobetasol Propionate and Tazarotene Lotion 0.01%\u002F0.045%",{"EARLY_PHASE1":2809,"PHASE1":2820,"PHASE2":2822,"PHASE3":2824,"PHASE4":2826,"NA":2828},{"trials":2810,"activeCount":12},[2811],{"nctId":2812,"briefTitle":2813,"status":112,"phases":2814,"primaryCompletion":2815,"completion":2815,"start":2772,"enrollment":2816,"conditions":2817,"interventions":2818},"NCT05282771","A Study Comparing Halobetasol Propionate and Tazarotene Topical Lotion 0.01%\u002F0.045% to Duobrii® Lotion (Halobetasol Propionate and Tazarotene Lotion), 0.01%\u002F0.045% (Reference Listed Drug) in the Treatment of Moderate to Severe Plaque Psoriasis.",[54],"2022-02-10",402,[18],[2807,2819],"Duobrii® Lotion (Halobetasol propionate and tazarotene lotion), 0.01%\u002F0.045%",{"trials":2821,"activeCount":12},[],{"trials":2823,"activeCount":12},[],{"trials":2825,"activeCount":12},[],{"trials":2827,"activeCount":12},[],{"trials":2829,"activeCount":12},[],{"intervention":2819,"totalTrials":119,"cells":2831},{"EARLY_PHASE1":2832,"PHASE1":2838,"PHASE2":2840,"PHASE3":2842,"PHASE4":2844,"NA":2846},{"trials":2833,"activeCount":12},[2834],{"nctId":2812,"briefTitle":2813,"status":112,"phases":2835,"primaryCompletion":2815,"completion":2815,"start":2772,"enrollment":2816,"conditions":2836,"interventions":2837},[54],[18],[2807,2819],{"trials":2839,"activeCount":12},[],{"trials":2841,"activeCount":12},[],{"trials":2843,"activeCount":12},[],{"trials":2845,"activeCount":12},[],{"trials":2847,"activeCount":12},[],{"intervention":2849,"totalTrials":119,"cells":2850},"Adapalene Gel 0.1%",{"EARLY_PHASE1":2851,"PHASE1":2863,"PHASE2":2865,"PHASE3":2867,"PHASE4":2869,"NA":2871},{"trials":2852,"activeCount":12},[2853],{"nctId":2854,"briefTitle":2855,"status":112,"phases":2856,"primaryCompletion":2857,"completion":2857,"start":2858,"enrollment":2859,"conditions":2860,"interventions":2861},"NCT04797793","A Study Comparing Adapalene Gel 0.1% and to Differin Gel in the Treatment of Acne Vulgaris",[54],"2021-01-08","2020-05-18",978,[15],[2849,2862],"Differin® Gel",{"trials":2864,"activeCount":12},[],{"trials":2866,"activeCount":12},[],{"trials":2868,"activeCount":12},[],{"trials":2870,"activeCount":12},[],{"trials":2872,"activeCount":12},[],{"intervention":2862,"totalTrials":119,"cells":2874},{"EARLY_PHASE1":2875,"PHASE1":2881,"PHASE2":2883,"PHASE3":2885,"PHASE4":2887,"NA":2889},{"trials":2876,"activeCount":12},[2877],{"nctId":2854,"briefTitle":2855,"status":112,"phases":2878,"primaryCompletion":2857,"completion":2857,"start":2858,"enrollment":2859,"conditions":2879,"interventions":2880},[54],[15],[2849,2862],{"trials":2882,"activeCount":12},[],{"trials":2884,"activeCount":12},[],{"trials":2886,"activeCount":12},[],{"trials":2888,"activeCount":12},[],{"trials":2890,"activeCount":12},[],{"intervention":2892,"totalTrials":119,"cells":2893},"TA103",{"EARLY_PHASE1":2894,"PHASE1":2904,"PHASE2":2906,"PHASE3":2908,"PHASE4":2910,"NA":2912},{"trials":2895,"activeCount":12},[2896],{"nctId":2897,"briefTitle":2898,"status":112,"phases":2899,"primaryCompletion":2900,"completion":2900,"start":2901,"enrollment":77,"conditions":2902,"interventions":2903},"NCT04883593","A Study Comparing the Efficacy of TA103 and the Placebo Control in the Treatment of Interdigital Tinea Pedis.",[54],"2021-02-20","2020-09-03",[21],[2892],{"trials":2905,"activeCount":12},[],{"trials":2907,"activeCount":12},[],{"trials":2909,"activeCount":12},[],{"trials":2911,"activeCount":12},[],{"trials":2913,"activeCount":12},[],{"intervention":837,"totalTrials":119,"cells":2915},{"EARLY_PHASE1":2916,"PHASE1":2922,"PHASE2":2924,"PHASE3":2926,"PHASE4":2928,"NA":2930},{"trials":2917,"activeCount":12},[2918],{"nctId":830,"briefTitle":831,"status":112,"phases":2919,"primaryCompletion":822,"completion":822,"start":833,"enrollment":834,"conditions":2920,"interventions":2921},[54],[15],[837,838,814],{"trials":2923,"activeCount":12},[],{"trials":2925,"activeCount":12},[],{"trials":2927,"activeCount":12},[],{"trials":2929,"activeCount":12},[],{"trials":2931,"activeCount":12},[],{"intervention":838,"totalTrials":119,"cells":2933},{"EARLY_PHASE1":2934,"PHASE1":2940,"PHASE2":2942,"PHASE3":2944,"PHASE4":2946,"NA":2948},{"trials":2935,"activeCount":12},[2936],{"nctId":830,"briefTitle":831,"status":112,"phases":2937,"primaryCompletion":822,"completion":822,"start":833,"enrollment":834,"conditions":2938,"interventions":2939},[54],[15],[837,838,814],{"trials":2941,"activeCount":12},[],{"trials":2943,"activeCount":12},[],{"trials":2945,"activeCount":12},[],{"trials":2947,"activeCount":12},[],{"trials":2949,"activeCount":12},[],{"intervention":2951,"totalTrials":119,"cells":2952},"Tretinoin Cream 0.025%",{"EARLY_PHASE1":2953,"PHASE1":2964,"PHASE2":2966,"PHASE3":2968,"PHASE4":2970,"NA":2972},{"trials":2954,"activeCount":12},[2955],{"nctId":2956,"briefTitle":2957,"status":112,"phases":2958,"primaryCompletion":2959,"completion":2959,"start":2960,"enrollment":2961,"conditions":2962,"interventions":2963},"NCT04724473","A Study Comparing Tretinoin Cream 0.025% and RETIN-A® Cream 0.025% in the Treatment of Acne Vulgaris",[54],"2020-11-21","2019-12-10",1030,[15],[2951],{"trials":2965,"activeCount":12},[],{"trials":2967,"activeCount":12},[],{"trials":2969,"activeCount":12},[],{"trials":2971,"activeCount":12},[],{"trials":2973,"activeCount":12},[]]